Crystalline prostacyclin (IP) receptor agonists and uses thereof
By developing the solid form of Ralipag, the problems of pharmacokinetic instability and frequent administration of existing prostacyclin receptor agonists in the treatment of PAH have been solved, and more stable efficacy and quality of life have been achieved. , suitable for PAH and other related diseases.
Patent Information
- Application Number
- CN202380024450.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-15
- Filing Date
- 2023-02-14
- Publication Date
- 2024-11-08
AI Technical Summary
Existing prostacyclin receptor agonists have problems with pharmacokinetic instability and frequent administration in the treatment of arterial pulmonary hypertension (PAH), which affects the efficacy and the quality of life of patients.
The solid form of Relipag, including crystalline and amorphous forms, and pharmaceutical compositions thereof, are developed, administered by oral, intranasal or inhalation routes, for activation of IP receptors, improved vasodilation and inhibition of platelet aggregation.
The solid form of Ralipag provides more stable drug release and longer half-life, reduces frequent dosing, improves the efficacy of PAH and the quality of life of patients, and is suitable for other related diseases such as thromboembolic pulmonary hypertension. wait.
Smart Images

Figure CN118922402A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 310,469, filed on February 15, 2022, which is incorporated herein by reference in its entirety. Technical Field
[0003] Described herein are solid-state forms of the prostacyclin (IP) receptor agonist ralinepag, as well as pharmaceutical compositions thereof, and methods of use thereof in treating diseases or conditions that may benefit from treatment with ralinepag. Background Art
[0004] Prostacyclin (IP) receptors are expressed on platelets and smooth muscle cells of several tissues (including lungs, heart, aorta, liver, kidneys and blood vessels). Activation of IP receptors leads to an increase in cellular cyclic adenosine monophosphate (cAMP), followed by vasodilation in arteries and inhibition of platelet aggregation. Replacement therapy for PGI2 has been shown to improve hemodynamics, exercise capacity and survival in the treatment of, for example, arterial pulmonary hypertension (PAH). Summary of the invention
[0005] The present disclosure relates to various solid forms of the prostacyclin (IP) receptor agonist lelipag. Such forms of lelipag are useful for modulating prostacyclin (IP) receptor agonist activity in mammals that may benefit from such activity.
[0006] In one aspect, described herein is a crystalline form of lelipag characterized by having: Figure 1 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; or Figure 2 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; or Figure 3 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; or Figure 4 An X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation.
[0007] In another aspect, described herein is a crystalline form of lelipag (Form 1) characterized by having Figure 1an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; or an XRPD pattern having peaks at 8.8±0.2°2θ, 11.7±0.2°2θ, 16.2±0.2°2θ, 21.3±0.2°2θ, 33.8±0.2°2θ, as measured using Cu Ka radiation.
[0008] In some embodiments, described herein is a crystalline form of lelipag (Form 1) characterized by having Fig.12a , Figure 12b , Fig.12c , Fig.12d , Fig.12e , Fig.12f , Fig.13a , Fig.13b , Fig.13c , Fig.13d , Fig.13e , Fig.14a , Fig.14b , Fig.14c , Fig.14d , Fig.14e , Fig.14f , Figure 14g , Fig.15a , Fig.15b , Fig.15c , Fig.16 , Fig.17a or Fig.17b , as measured using Cu Ka radiation.
[0009] In some embodiments, the crystalline form of lelipag (Form 1) is further characterized as having: Figure 6 a thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram substantially the same as shown in Figure 7 A differential scanning calorimetry (DSC) thermogram substantially the same as shown in FIG.
[0010] In some embodiments, the crystalline form of lelipag (Form 1) is further characterized as having: a differential thermal analysis (DTA) thermogram showing a sharp endothermic event with an onset at about 127.2°C; and a differential scanning calorimetry (DSC) thermogram showing a sharp endothermic event with an onset at about 127.5°C.
[0011] In some embodiments, the crystalline form of lelipag (Form 1) is further characterized as having a reversible water uptake of 0.1% (w / w) between 0% and 90% relative humidity (RH).
[0012] In some embodiments, crystalline Form 1 of lelipag is further characterized as having an XRPD that is unchanged after dynamic vapor sorption (DVS) analysis between 0% and 90% RH.
[0013] In another aspect, described herein is a crystalline form of lelipag (Form 1) characterized as having unit cell parameters at 100K substantially equal to:
[0014]
[0015] In yet another aspect, described herein is a crystalline form of lelipag (Form 2) characterized by having Figure 2 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; or an XRPD pattern having peaks at 4.1±0.2°2θ, 15.5±0.2°2θ, 16.9±0.2°2θ, 17.9±0.2°2θ, 22.8±0.2°2θ, 23.7±0.2°2θ, as measured using Cu Ka radiation.
[0016] In some embodiments, the crystalline form of lelipag (Formula 2) is further characterized as having Figure 8 In some embodiments, the crystalline form of lelipag (Formula 2) is further characterized as having a differential thermal analysis (TGA / DTA) thermogram showing weak endothermic and exothermic events from 81°C to 89°C and a broad endothermic event with an onset at about 124.7°C. In some embodiments, the crystalline form of lelipag (Formula 2) is further characterized as having an XRPD that converts to the crystalline form of lelipag (Form 1) upon heating. In some embodiments, the crystalline form of lelipag (Formula 2) is further characterized as a dimethyl sulfoxide solvate.
[0017] In yet another aspect, described herein is a crystalline form of lelipag (Form 3) characterized by having Figure 3 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; or an XRPD pattern having peaks at 3.6±0.2°2θ, 18.7±0.2°2θ, 22.2±0.2°2θ, 24.2±0.2°2θ, 24.3±0.2°2θ, as measured using Cu Ka radiation.
[0018] In some embodiments, the crystalline form of lelipag (Form 3) is further characterized as having Fig. 9In some embodiments, the crystalline form of lelipag (Form 3) is further characterized as having a thermogravimetric analysis (TGA) trace showing a mass loss of about 17.8% from the onset of heating to about 238°C. In some embodiments, the crystalline form of lelipag (Form 3) is further characterized as having a differential thermal analysis (DTA) thermogram showing a sharp endothermic event with an onset at about 74.6°C. In some embodiments, the crystalline form of lelipag (Form 3) is further characterized as a hydrate.
[0019] In yet another aspect, described herein is a crystalline form of lelipag (Formula 4) characterized by having Figure 4 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; or an XRPD pattern having peaks at 15.0±0.2°2θ, 16.7±0.2°2θ, 18.0±0.2°2θ, 18.7±0.2°2θ, 18.9±0.2°2θ, as measured using Cu Ka radiation.
[0020] In some embodiments, the crystalline form of lelipag (Formula 4) is further characterized as having Fig.10 In some embodiments, the crystalline form of lelipag (Formula 4) is further characterized as having a differential thermal analysis (DTA) thermogram showing a broad endothermic event with an onset at about 29.0°C, a sharp endothermic event with an onset at about 127.8°C, or both. In some embodiments, the crystalline form of lelipag (Formula 4) is further characterized as having an XRPD that converts to the crystalline form of lelipag (Form 1) upon drying. In some embodiments, the crystalline form of lelipag is further characterized as having an XRPD that converts to amorphous lelipag upon drying.
[0021] In yet another aspect, described herein is an amorphous form of lelipag characterized by having an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity. In some embodiments, the amorphous form of lelipag is further characterized as lelipag (Form 1) that converts to a crystalline form upon drying.
[0022] Also described herein are pharmaceutical compositions comprising crystalline lelipag described herein and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is formulated in the form of a solid form pharmaceutical composition suitable for administration to a subject by oral administration, intranasal administration, or inhalation. In some embodiments, the pharmaceutical composition is formulated in the form of a solid form pharmaceutical composition for oral administration to a mammal. In some embodiments, the pharmaceutical composition is in the form of a tablet, pill, or capsule. In some embodiments, the pharmaceutical composition is administered with a dry powder inhaler (DPI) or a metered dose inhaler (MDI).
[0023] Also described herein is a pharmaceutical composition comprising amorphous lelipag and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is formulated as a solid form pharmaceutical composition suitable for administration to a subject by oral administration, intranasal administration or inhalation. In some embodiments, the pharmaceutical composition is formulated as a solid form pharmaceutical composition for oral administration to a mammal. In some embodiments, the pharmaceutical composition is in the form of a tablet, pill or capsule. In some embodiments, the pharmaceutical composition is administered with a dry powder inhaler (DPI) or a metered dose inhaler (MDI).
[0024] In one aspect, described herein are methods of treating arterial pulmonary arterial hypertension (PAH) in a subject in need thereof comprising administering crystalline lelipag or amorphous lelipag, or a pharmaceutical composition comprising crystalline lelipag or amorphous lelipag. In some embodiments, PAH is selected from: idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease selected from scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis, and dermatomyositis; PAH associated with a congenital heart disease selected from atrial septic defect (ASD), ventricular septic defect (VSD), and patent ductus arteriosus in a patient; PAH associated with portal hypertension; PAH associated with HIV infection; PAH associated with ingestion of drugs or toxins; PAH associated with hereditary hemorrhagic telangiectasia; PAH associated with splenectomy; PAH associated with significant venous or capillary involvement; PAH associated with pulmonary veno-occlusive disease (PVOD), and PAH associated with pulmonary capillary hemangiomatosis (PCH) in a patient. In some embodiments, PAH is a PAH of World Health Organization (WHO) Group 1. In some embodiments, the subject has WHO / NYHA functional class II to IV symptoms.
[0025] In one aspect, described herein is a method for synthesizing amorphous lelipag, wherein the amorphous lelipag is characterized as having an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity, the method comprising converting lelipag of Form 1, Form 3, Pattern 2, or Pattern 4 into an amorphous form. In some embodiments, the method comprises drying lelipag of crystalline Pattern 4. In some embodiments, the method comprises freeze-drying a lelipag solution in an organic solvent. In some embodiments, the organic solvent is 1,4-dioxane. In some embodiments, the concentration of the lelipag solution is at most 5 mg / mL. In some embodiments, the concentration of the lelipag solution is at most 3 mg / mL.
[0026] Other objects, features and advantages of the compounds, methods and compositions described herein will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, while indicating particular embodiments, are given by way of illustration only, since various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The features of the present invention are particularly set forth in the appended claims. The features of the present invention will be better understood by referring to the following detailed description and the accompanying drawings, in which illustrative embodiments utilizing the principles of the present invention are set forth, wherein:
[0028] Figure 1 An X-ray powder diffraction (XRPD) pattern of lelipag in crystalline Form 1 is shown.
[0029] Figure 2 The X-ray powder diffraction (XRPD) pattern of lelipag in crystalline form 2 is shown.
[0030] Figure 3 An X-ray powder diffraction (XRPD) pattern of crystalline Form 3 of lelipag is shown.
[0031] Figure 4 The X-ray powder diffraction (XRPD) pattern of lelipag in crystalline form 4 is shown.
[0032] Figure 5 The X-ray powder diffraction (XRPD) pattern of amorphous lelipag is shown.
[0033] Figure 6 Shown is a thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram of crystalline Form 1 of lelipag.
[0034] Figure 7 A differential scanning calorimetry (DSC) thermogram of lelipag in crystalline Form 1 is shown.
[0035] Figure 8 Thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram of lelipumigrate of crystalline form 2 is shown.
[0036] Fig. 9 Shown is a thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram of crystalline Form 3 of lelipag.
[0037] Fig.10 Thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram of lelipumig in crystalline form 4 is shown.
[0038] Fig.11 An overlay of simulated (top) and experimental (bottom) XRPD diffraction patterns of lelipag in crystalline Form 1 is shown.
[0039] Figures 12a to 12f Shown are X-ray powder diffraction (XRPD) patterns of crystalline Form 1 of lelipag obtained from the solvent solubility study screening in Example 3. All figures show at the top a reference X-ray powder diffraction (XRPD) pattern of Form 1. XRPD patterns labeled with (PO) correspond to preferred orientations.
[0040] Figures 13a to 13e Shown are X-ray powder diffraction (XRPD) patterns of crystalline Form 1 of lelipag obtained after thermal cycling experiments in Example 4. All figures show at the top a reference XRPD pattern of Form 1. XRPD patterns labeled with (PO) correspond to preferred orientations.
[0041] Figures 14a to 14e Shown is an X-ray powder diffraction (XRPD) pattern of crystalline Form 1 of lelipag obtained from Example 4 after thermal cycling and drying in a vacuum oven at 40°C. All figures show at the top a reference X-ray powder diffraction (XRPD) pattern of Form 1. The XRPD patterns labeled with (PO) correspond to the preferred orientation.
[0042] Fig.14f Shown is an X-ray powder diffraction (XRPD) pattern of lelipag in crystalline Form 1 after thermal cycling. Only Form 1 was recovered in all samples upon drying.
[0043] Figure 14g X-ray powder diffraction (XRPD) patterns of lelipag in crystallized Form 1 after thermal cycling are shown. Form 1 was produced from 3 of the 5 solids recovered after thermal cycling. This form was retained upon drying. Amorphous solids from DMA / water and NMP / water were found to dry to Form 1.
[0044] Figures 15a to 15cAn X-ray powder diffraction (XRPD) pattern of lelipag in crystalline Form 1 obtained after evaporation of the mother liquor in Example 4 is shown. (The last depicted sample was obtained after addition of an antisolvent to the mother liquor in Example 4). All figures show at the top a reference X-ray powder diffraction (XRPD) pattern of Form 1. The XRPD patterns marked with (PO) correspond to preferred orientations.
[0045] Fig.16 Shown is an X-ray powder diffraction (XRPD) pattern of isolated crystalline Form 1 of lelipag obtained after rapid cooling of the mother liquor in Example 4. All figures show at the top a reference X-ray powder diffraction (XRPD) pattern of Form 1. The XRPD patterns marked with (PO) correspond to the preferred orientation.
[0046] Fig.17a and 17b Shown is an X-ray powder diffraction (XRPD) pattern of crystalline Form 1 of lelipag obtained after addition of an antisolvent to the mother solution in Example 4. All figures show at the top a reference X-ray powder diffraction (XRPD) pattern of Form 1. The XRPD patterns marked with (PO) correspond to the preferred orientation. DETAILED DESCRIPTION
[0047] Although small molecule inhibitors are usually initially evaluated for their activity when dissolved in solution, solid state characteristics such as polymorphism are also important. The polymorphic forms of bulk drugs can have different physical properties, including melting points, apparent solubility, dissolution rate, optical and mechanical properties, vapor pressure and density. These properties can have a direct impact on the ability to process or manufacture bulk drugs and drug products. In addition, the differences in these properties can and often lead to different pharmacokinetic characteristics of different polymorphic forms of drugs. Therefore, under the regulatory review of the "sameness" of drug products from various manufacturers, polymorphism is often an important factor.
[0048] Pulmonary arterial hypertension (PAH), PGI2, and IP receptor agonists
[0049] Pulmonary hypertension (PH) is a rare progressive disease characterized by elevated pulmonary vascular resistance (PVR), which can lead to right ventricular enlargement, hypertrophy, heart failure and ultimately death. According to the current World Health Organization (WHO) classification, there are five different PH groups based on different causes. These are called PH WHO groups. Group 1 is arterial pulmonary hypertension (PAH), which is characterized by thickening and hardening of the pulmonary vessels. Although PAH management capabilities have improved significantly in the past 15 years, mortality remains unacceptably high, with a median life expectancy of 7 years after diagnosis. WHO Group 2 includes PH due to left heart disease. In these patients, cardiac problems rather than pulmonary vascular problems are primarily responsible for the disease state. WHO Group 3 includes PH due to chronic lung disease and / or hypoxia (low oxygen levels). Group 3 includes pulmonary hypertension associated with interstitial lung disease (PH-ILD) and PH associated with pulmonary fibrosis. WHO Group 4 is called chronic thromboembolic pulmonary hypertension (CTEPH). WHO Group 5 is a situation in which PH is secondary to other diseases in a way that is not well understood. Treatment depends on the form of PH. For example, PAH is often treated with prostacyclin. Regardless of classification, PH is a serious and often fatal disease.
[0050] The severity of PH (including PAH) is graded into four functional categories according to a system originally developed by the New York Heart Association (NYHA) for heart failure and then modified by the WHO for patients with PAH. Patients are usually asymptomatic in the earliest stages of the disease (i.e., functional class I), but as the disease progresses, their symptoms (including exertional dyspnea, fatigue, peripheral edema, and syncope) may be indistinguishable from other cardiopulmonary diseases. Many patients are not diagnosed until they have developed WHO / NYHA functional class II or III symptoms.
[0051] Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction, remodeling of the pulmonary vascular wall, and thrombosis contribute to increased pulmonary vascular resistance in PAH (Humbert et al., J. Am. Coll. Cardiol., 2004, 43: 13S-24S).
[0052] The compounds disclosed herein are useful in treating arterial pulmonary hypertension (PAH) and its symptoms. PAH should be understood to encompass all forms of arterial pulmonary hypertension described in the 2003 World Health Organization (WHO) Clinical Classification of Arterial Pulmonary Hypertension. Those forms include idiopathic PAH (IPAH); familial PAH (FPAH); PAH associated with other conditions (APAH), such as PAH associated with collagen vascular disease, PAH associated with congenital body-to-pulmonary shunts, PAH associated with portal hypertension, PAH associated with HIV infection, PAH associated with drugs or toxins, or PAH associated with others; and PAH associated with significant venous or capillary involvement.
[0053] Idiopathic PAH refers to PAH of unknown cause.
[0054] Familial PAH refers to PAH that is suspected or confirmed to be genetically transmitted.
[0055] PAH associated with collagen vascular disease should be understood to encompass PAH associated with scleroderma, PAH associated with CREST (calcinosis cutis, Raynaud's phenomenon, esophageal dysfunction, scleroderma, and telangiectasia) syndrome, PAH associated with systemic lupus erythematosus (SLE), PAH associated with rheumatoid arthritis, PAH associated with Takayasu's arteritis, PAH associated with polymyositis, and PAH associated with dermatomyositis.
[0056] PAH associated with congenital systemic-pulmonary shunt should be understood to encompass PAH associated with atrial septic defects (ASD), PAH associated with ventricular septic defects (VSD), and PAH associated with patent ductus arteriosus.
[0057] PAHs associated with drugs or toxins should be understood to encompass PAHs associated with ingestion of amyrex, PAHs associated with ingestion of fenfluramine compounds (e.g., PAHs associated with ingestion of fenfluramine or PAHs associated with ingestion of dexfenfluramine), PAHs associated with ingestion of certain toxic oils (e.g., PAHs associated with ingestion of canola oil), PAHs associated with ingestion of pyrrolizidine alkaloids (e.g., PAHs associated with ingestion of bush tea), and PAHs associated with ingestion of monocrotaline.
[0058] PAH associated with others should be understood to encompass PAH associated with thyroid disorders, PAH associated with glycogen storage diseases, PAH associated with Gaucher disease, PAH associated with hereditary hemorrhagic telangiectasia, PAH associated with hemoglobinopathies, PAH associated with myeloproliferative disorders, and PAH associated with splenectomy.
[0059] PAH associated with significant venous or capillary involvement should be understood to encompass PAH associated with pulmonary veno-occlusive disease (PVOD) and PAH associated with pulmonary capillary hemangiomatosis (PCH). (See, e.g., Simonneau et al., J. Am. Coll. Cardiol., 2004, 43:5S-12S; McGoon et al., Chest, 2004, 126:14S-34S; Rabinovitch, Annu. Rev. Pathol. Mech. Dis., 2007, 2:369-399; McLaughlin et al., Circulation, 2006, 114:1417-1431; Strauss et al., Clin. Chest. Med., 2007, 28:127-142; Taichman et al., Clin. Chest. Med., 2007, 28:1-22).
[0060] Badesch et al. presented evidence for the association of PAH with scleroderma and the beneficial effects of PGI2 receptor agonists on PAH (Badesch et al., Ann. Intern. Med., 2000, 132: 425-434). Humbert et al. demonstrated evidence for the association of PAH with collagen vascular disease mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE), Sjögren's syndrome and CREST syndrome and the beneficial effects of PGI2 receptor agonists on PAH (Eur. Respir. J., 1999, 13: 1351-1356). Miwa et al. presented evidence for the association of PAH with CREST syndrome and the beneficial effects of PGI2 receptor agonists on PAH (Int. Heart J., 2007, 48: 417-422). Robbins et al. showed evidence for the association of PAH with SLE and the beneficial effects of PGI2 receptor agonists on PAH (Chest, 2000, 117: 14-18). Aguilar et al. described the association of PAH with HIV infection and evidence for the beneficial effects of PGI2 receptor agonists on PAH (Am. J. Respir. Crit. Care Med., 2000, 162: 1846-1850). Rosenzweig et al. published evidence for the association of PAH with congenital heart defects (including ASD, VSD and patent ductus arteriosus) and the beneficial effects of PGI2 receptor agonists on PAH (Circulation, 1999, 99: 1858-1865). Archer et al. presented evidence for the association of PAH with fenfluramine or dexfenfluramine or anorexigens (Am. J. Respir. Crit. Care Med., 1998, 158: 1061-1067). McGoon et al. demonstrated evidence for the association of PAH with hereditary hemorrhagic telangiectasia (Chest, 2004, 126: 14-34). Hoeper et al. presented evidence for an association between PAH and splenectomy (Ann. Intern. Med., 1999, 130:506-509). Hoeper et al. showed evidence for an association between PAH and portal hypertension and a beneficial effect of PGI2 receptor agonists on PAH (Eur. Respir. J., 2005, 25:502-508).
[0061] Symptoms of PAH include dyspnea, angina, syncope, and edema (McLaughlin et al., Circulation, 2006, 114: 1417-1431).The compounds disclosed herein are useful in treating symptoms of PAH.
[0062] In some embodiments, arterial pulmonary hypertension (PAH) is selected from: idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease selected from the following items: scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis, Takayasu's arteritis, polymyositis and dermatomyositis; PAH associated with a congenital heart disease selected from the following items: atrial septic defect (ASD), ventricular septic defect (VSD) and patent ductus arteriosus in patients; PAH associated with portal hypertension; PAH associated with HIV infection; PAH associated with ingestion of drugs or toxins; PAH associated with hereditary hemorrhagic telangiectasia; PAH associated with splenectomy; PAH associated with significant venous or capillary involvement; PAH associated with pulmonary veno-occlusive disease (PVOD) and PAH associated with pulmonary capillary hemangiomatosis (PCH) in patients.
[0063] Studies have shown that patients with PAH have alterations in prostacyclin and thromboxane A2 activity, including increased endothelin synthesis and decreased expression of nitric oxide synthase in the pulmonary arterial system, all of which contribute to vasoconstriction / vasodilation imbalance, thrombosis, cell proliferation, and pulmonary artery wall remodeling. Currently available pharmacological therapies for PAH target the prostacyclin (also known as prostaglandin I2 [PGI2]), endothelin, and nitric oxide pathways.
[0064] Guidelines for the treatment of PAH support the use of oral endothelin receptor antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase (sGC) stimulators as monotherapy or in combination for patients with PAH with WHO / NHYA functional class III. ERAs target the endothelin pathway, whereas PDE5-Is and sGC stimulators target the nitric oxide pathway. There are three commercially available ERAs, ambrisentan, bosentan, and macitentan; two commercially available PDE5-Is, sildenafil and tadalafil; and one commercially available sGC stimulator, riociguat, approved for the treatment of PAH. These drugs may improve exercise capacity, symptoms, and / or cardiopulmonary hemodynamic variables in patients with symptomatic PAH. Uncertainty exists regarding whether they prolong survival in this population.
[0065] PGI2 is a metabolite of arachidonic acid and is formed via the cyclooxygenase pathway. Endothelial cells are the main source of PGI2. The vascular effects of PGI2 and its mimetics are mainly mediated by the activation of PGI2 (IP) receptors, and include vasodilation, inhibition of smooth muscle cell proliferation and inhibition of platelet aggregation. IP receptors are expressed on platelets and smooth muscle cells of several tissues (including lungs, heart, aorta, liver, kidneys and blood vessels). The activation of IP receptors causes cell cyclic adenosine monophosphate (cAMP) to increase, followed by vasodilation in arteries and inhibition of platelet aggregation. For PGI2 replacement therapy, improved hemodynamics, exercise capacity and survival have been clearly demonstrated.
[0066] Epoprostenol (Epoprostenol), a synthetic PGI2 analog, is a potent vasodilator and inhibitor of platelet aggregation and is the first therapeutic agent approved for PAH therapy. Compared with conventional therapy, epoprostenol improves the prognosis of patients with PAH, validating the IP receptor as a target for PAH therapy. However, epoprostenol requires continuous infusion via a mobile pump, is unstable at room temperature, and is associated with intravenous catheter-related infections and thrombosis. According to the treatment algorithm proposed by the 5th World Symposium and the European Society of Cardiology / European Respiratory Society (ESC / ERS) guidelines, injectable prostacyclin analogs should be administered in patients with PAH severity classified as WHO / NYHA functional class III to IV.
[0067] Subsequent PGI2 analogs, such as treprostinil (continuous subcutaneous and intravenous infusion, intermittent inhalation, and oral) and iloprost (intermittent inhalation), have demonstrated efficacy through improved exercise capacity and / or delay of clinical symptom deterioration. These prostacyclins are prescribed for patients with WHO / NYHA functional II to IV PAH. Although these prostacyclin analogs address some of the limitations associated with epoprostenol, they have the disadvantages of frequent dosing (iloprost) and injection site pain (subcutaneous treprostinil) in addition to typical prostacyclin-related side effects such as headache, nausea, flushing, diarrhea, and jaw pain.
[0068] Selexipag is an oral selective IP receptor agonist approved for the treatment of PAH in the United States and elsewhere to delay disease progression and reduce the risk of hospitalization for PAH. The ESC / ERS guidelines recommend the use of Selexipag to treat patients with PAH of severity WHO / NYHA functional class II to III. Although Selexipag and its active metabolites have a mode of action similar to that of endogenous prostacyclins (IP receptor agonism), they are chemically different from prostacyclin analogs with different pharmacological properties. Selexipag has been shown to reduce PVR after 17 weeks of treatment and demonstrated a 40% reduction in the composite morbidity and mortality endpoints. However, the short effective half-life (3 to 4 hours) of the active metabolite of Selexipag results in relatively large fluctuations between peak plasma concentrations and trough plasma concentrations after BID administration.
[0069] Despite the availability of treatments, functional limitations and survival of patients with PAH remain unsatisfactory. The success of selexipag in delaying disease progression and reducing the risk of hospitalization for PAH supports the utility of oral prostacyclin therapy and paves the way for further optimization of non-prostaglandin IP receptor agonists. Research efforts have focused on optimizing non-prostaglandin IP receptor activation, bioavailability, and PK in an effort to provide sustained and potent target engagement with an oral formulation that provides clinical efficacy similar to that of parenteral prostacyclins.
[0070] As described herein, lelipag, as well as its crystalline forms and amorphous phases, and pharmaceutical compositions thereof, may be attractive oral alternatives to currently approved oral prostacyclin analogs and non-prostaglandin IP receptor agonists for the treatment of PAH. In some embodiments, the compounds disclosed herein are useful in treating PH other than PAH. For example, the compounds disclosed herein are useful for treating Group 3 forms of PH, such as PH-ILD or PH associated with pulmonary fibrosis.
[0071] The methods and compositions of the present disclosure may also be useful for treating other conditions such as platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in individuals undergoing angioplasty or coronary artery bypass surgery or in individuals with atrial fibrillation; atherothrombosis; asthma or its symptoms; diabetes-related conditions such as diabetic peripheral neuropathy, diabetic nephropathy, or diabetic retinopathy; glaucoma or other eye diseases with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disease (COPD).
[0072] In some embodiments, the methods and compositions disclosed herein are useful for treating chronic thromboembolic pulmonary hypertension (CTEPH). In some embodiments, the methods and compositions disclosed herein are useful for treating persistent / recurrent CTEPH (WHO Group 4) after surgical treatment. In some embodiments, the methods and compositions disclosed herein are useful for treating inoperable CTEPH to improve exercise capacity and / or WHO functional class.
[0073] Rayleigh Pag
[0074] Lelipag refers to "2-([(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)-cyclohexyl]methoxy)acetic acid", "acetic acid, 2-((trans-4-(((((4-chlorophenyl)phenylamino)-carbonyl)oxy)methyl)cyclohexyl)methoxy)-", "2-((trans-4-((((4-chlorophenyl)(phenyl)carbamoyl)-oxy)methyl)cyclohexyl)methoxy)acetic acid" or "APD-811". Other names may be known.
[0075] Raleigh Pag has the following chemical structure:
[0076]
[0077] Lelipag is an oral, potent and selective IP receptor agonist developed for the treatment of PAH. Lelipag has been characterized in single-dose and multiple-dose studies in healthy volunteers. 1 / 2 Longer than that of selexipag (and its active metabolite MRE-269), with less variability in plasma concentrations between doses (peak:trough ratio). The relatively short half-life of selexipag results in the need for BID dosing.
[0078] The safety profile showed that dose-related pharmacology at the IP receptor occurred within the lower dose range of 0.01 mg to 0.2 mg, with side effects consistent with those reported for IP receptor agonists. Head-to-head in vitro studies have demonstrated that lelipag is more potent and effective than selexipag at increased cellular cAMP levels, resulting in improved pulmonary artery vasodilation and better inhibition of human pulmonary artery smooth muscle cell (PASMC) proliferation.
[0079] Lelipag results in improved vasodilation and inhibition of smooth muscle proliferation, which may be an attractive oral alternative to currently available oral prostacyclin analogs and non-prostaglandin IP receptor agonists for the treatment of PAH.
[0080] One embodiment herein provides a method of agonizing an IP receptor comprising contacting the IP receptor with lelipag or a solid form thereof disclosed herein.
[0081] The preparation of lelipag has been previously described (see, WO 2009 / 117095, US 8,895,776, US 10,668,033, and US 2020 / 0375930, each of which is herein incorporated by reference in its entirety).
[0082] In some embodiments, lelipag is amorphous. As used herein, the term "amorphous" or "amorphous solid form" or "amorphous phase" refers to a solid form that lacks crystallinity.
[0083] In some embodiments, lelipag is crystalline. In some embodiments, crystallinity is determined by methods known in the art.
[0084] In some embodiments, the crystallinity of the solid form is determined by X-ray powder diffraction (XRPD). In some embodiments, the crystallinity of the solid form is determined by solid-state NMR. In some embodiments, the crystallinity of the solid form is determined by Fourier transform IR spectroscopy (FTIR).
[0085] If multiple diffraction patterns are available, an assessment of particle statistics (PS) and / or preferred orientation (PO) is possible. The consistency of relative intensity among the XRPD patterns from multiple diffractometers indicates good orientation statistics. Alternatively, the observed XRPD patterns can be compared with the XRPD patterns calculated based on the single crystal structure (if available). The two-dimensional scattering pattern using an area detector can also be used to assess PS / PO. If the effects of both PS and PO are determined to be negligible, the XRPD pattern is representative of the powder average intensity of the sample, and significant peaks can be identified as "representative peaks". In general, the more data collected to determine representative peaks, the more confident the classification of those peaks.
[0086] "Characteristic peaks" are a subset of representative peaks to the extent they are present, and are used to distinguish one crystalline polymorph from another (a polymorph is a crystalline form having the same chemical composition). Characteristic peaks are determined by evaluating which representative peaks, if any, are present in one crystalline polymorph of a compound within ±0.2° 2θ for all other known crystalline polymorphs of the compound. Not all crystalline polymorphs of a compound necessarily have at least one characteristic peak.
[0087] The term "preferred orientation" as used herein refers to an extreme case of non-random distribution of crystallites in a solid state form. In XRPD, an ideal sample is uniform and the crystallites are randomly distributed in the bulk solid. In a truly random sample, each possible reflection from a given set of planes will have an equal number of crystallites contributing to it. However, this is not the case when the solid state form is in a preferred orientation. Therefore, comparing the intensity between a random orientation diffraction pattern and a preferred orientation diffraction pattern may look completely different. Quantitative analysis that depends on intensity ratios is greatly distorted by preferred orientation. Careful sample preparation is important for reducing the incidence of preferred orientations.
[0088] Amorphous Rayleigh Pug
[0089] Provided herein are amorphous lelipag. Some embodiments provide compositions comprising amorphous lelipag.
[0090] In some embodiments, amorphous lelipag is characterized as having an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity.
[0091] In one aspect, described herein is a method for synthesizing amorphous lelipag, wherein the amorphous lelipag is characterized as having an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity, the method comprising converting Form 1, Form 3, Pattern 2, or Pattern 4 of lelipag into an amorphous form. In some embodiments, the method comprises drying crystalline Pattern 4 lelipag. In some embodiments, the method comprises drying crystalline Form 1 lelipag. In some embodiments, the method comprises lyophilizing a lelipag solution in an organic solvent. In some embodiments, the organic solvent is 1,4-dioxane. In some embodiments, the concentration of the lelipag solution is at most 10 mg / mL. In some embodiments, the concentration of the lelipag solution is at most 5 mg / mL. In some embodiments, the concentration of the lelipag solution is at most 4 mg / mL. In some embodiments, the concentration of the lelipag solution is at most 3 mg / mL. In some embodiments, the concentration of the lelipag solution is at most 2 mg / mL. In some embodiments, the concentration of the lelipag solution is up to 1 mg / mL. In some embodiments, the concentration of the lelipag solution is about 0.1 mg / ml to about 5 mg / mL. In some embodiments, the concentration of the lelipag solution is about 0.1 mg / ml to about 3 mg / mL. In some embodiments, the concentration of the lelipag solution is about 0.1 mg / ml to about 4 mg / mL.
[0092] Crystalline Rayleigh Pug
[0093] Crystalline lelipampug is also provided herein.
[0094] In some embodiments, crystalline lelipag is unsolvated.
[0095] In some embodiments, crystalline lelipag is solvated. In some embodiments, crystalline lelipag is a dimethyl sulfoxide solvate.
[0096] In some embodiments, crystalline lelipag is a hydrate.
[0097] Lelipag in crystalline form 1
[0098] In some embodiments, crystalline lelipag is crystalline form 1 lelipag. In some embodiments, described herein are compositions comprising crystalline form 1 lelipag. In some embodiments, crystalline form 1 lelipag is referred to as crystalline pattern 1 lelipag.
[0099] In some embodiments, lelipag in crystalline Form 1 is anhydrous. In some embodiments, lelipag in crystalline Form 1 is not solvated. In some embodiments, lelipag in crystalline Form 1 is not hydrated.
[0100] In some embodiments, crystalline Form 1 of lelipag is formed from other solid state forms described herein. In some embodiments, crystalline Form 1 of lelipag is a thermodynamically favored solid state form of lelipag.
[0101] In some embodiments, crystalline Form 1 of lelipag is characterized as having Figure 1 An X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation.
[0102] In some embodiments, crystalline Form 1 of lelipag is characterized by having an XRPD pattern with peaks at 8.8±0.2°2θ, 11.7±0.2°2θ, 16.2±0.2°2θ, 21.3±0.2°2θ, 33.8±0.2°2θ as measured using Cu Ka radiation.
[0103] In some embodiments, crystalline Form 1 of lelipag is characterized by having an XRPD pattern with peaks at 8.8±0.2° 2θ, 11.7±0.2° 2θ, and 16.2±0.2° 2θ as measured using Cu Ka radiation.
[0104] In some embodiments, crystalline Form 1 of lelipag is characterized as having: Figure 6 Thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermograms substantially the same as shown in .
[0105] In some embodiments, crystalline Form 1 of lelipag is characterized as having a differential thermal analysis (DTA) thermogram showing a sharp endothermic event with an onset at about 127.2°C.
[0106] In some embodiments, crystalline Form 1 of lelipag is characterized as having: Figure 7 A differential scanning calorimetry (DSC) thermogram substantially the same as shown in FIG.
[0107] In some embodiments, crystalline Form 1 of lelipag is characterized as having a DSC thermogram having a sharp endothermic event with an onset at about 127.5°C.
[0108] In some embodiments, crystalline Form 1 of lelipag is characterized as having: a reversible water uptake of 0.1% (w / w) between 0% and 90% relative humidity (RH).
[0109] In some embodiments, crystalline Form 1 of lelipag is characterized as having an XRPD that is unchanged after dynamic vapor sorption (DVS) analysis between 0% and 90% RH.
[0110] In some embodiments, crystalline Form 1 of lelipag is characterized as having unit cell parameters at 100K substantially equal to:
[0111]
[0112] In some embodiments, crystalline Form 1 of lelipag is characterized as having:
[0113] and Figure 1 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; and
[0114] and Figure 6 A thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram substantially the same as shown in ;
[0115] or with Figure 7 a differential scanning calorimetry (DSC) thermogram substantially the same as shown in ; or both.
[0116] In some embodiments, crystalline Form 1 of lelipag is characterized as having:
[0117] An XRPD pattern having peaks at 8.8±0.2°2θ, 11.7±0.2°2θ, 16.2±0.2°2θ, 21.3±0.2°2θ, 33.8±0.2°2θ, as measured using Cu Ka radiation; and a differential thermal analysis (DTA) thermogram showing a sharp endothermic event with an onset at about 127.2°C; or a DSC thermogram having a sharp endothermic event with an onset at about 127.5°C; or both.
[0118] In some embodiments, crystalline Form 1 of lelipag is characterized as having:
[0119] an XRPD pattern having peaks at 8.8±0.2° 2θ, 11.7±0.2° 2θ, and 16.2±0.2° 2θ as measured using Cu Ka radiation; and
[0120] Showing a differential thermal analysis (DTA) thermogram with a sharp endothermic event with an onset at about 127.2°C; or a DSC thermogram with a sharp endothermic event with an onset at about 127.5°C; or both.
[0121] In some embodiments, crystalline Form 1 of lelipag is characterized as having Figure 6 In some embodiments, the crystalline form 1 of Leleipag is characterized as having a DTA thermogram showing a sharp endothermic event with an onset at about 127.2°C. In some embodiments, the crystalline form 1 of Leleipag is characterized as having: a DTA thermogram showing a sharp endothermic event with an onset at about 127.2°C and a peak at about 129.5°C. In some embodiments, the DTA thermograms of other solid forms show endothermic events with an onset of 125°C-128°C, which can be attributed to the formation of the crystalline form 1 of Leleipag by DTA experiments. In some embodiments, the crystalline form 1 of Leleipag is characterized as having: Figure 7In some embodiments, the crystalline form 1 of Leleipag is characterized as having a DSC thermogram with a sharp endothermic event with an onset at about 127.5°C. In some embodiments, the crystalline form 1 of Leleipag is characterized as having: a DSC thermogram with a sharp endothermic event with an onset at about 127.5°C and a peak at about 129.2°C. In some embodiments, the DSC thermograms of other solid forms show an endothermic event with an onset of 125°C-128°C, which can be attributed to the formation of the crystalline form 1 of Leleipag by DSC experiments. In some embodiments, the crystalline form 1 of Leleipag is characterized as having a reversible water absorption of 0.1% (w / w) between 0% and 90% relative humidity (RH). In some embodiments, the crystalline form 1 of Leleipag is characterized as having an XRPD that is unchanged after dynamic vapor sorption (DVS) analysis between 0% and 90% RH.
[0122] In some embodiments, crystalline Form 1 of lelipag is characterized as having unit cell parameters at 100K substantially equal to:
[0123]
[0124] In some embodiments, lelipag in crystalline Form 1 has an XRPD pattern that exhibits a preferred orientation. In some embodiments, lelipag in crystalline Form 1 has an XRPD pattern that exhibits some peaks having intensities greater than those observed from samples that are not in a preferred orientation. In some embodiments, lelipag in crystalline Form 1 has an XRPD pattern that exhibits only one or two peaks corresponding to a preferred orientation.
[0125] Crystal Pattern 2 Rayleigh Pagle
[0126] In some embodiments, crystalline lelipag is lelipag in crystalline Form 2. In some embodiments, compositions comprising crystalline Form 2 lelipag are described herein.
[0127] In some embodiments, crystalline Form 2 is formed by lyophilization. In some embodiments, crystalline Form 2 is formed solely by lyophilization. In some embodiments, lelipipag in crystalline Form 2 has poor crystallinity.
[0128] In some embodiments, lelipag in crystalline Form 2 is anhydrous. In some embodiments, lelipag in crystalline Form 2 is not solvated. In some embodiments, lelipag in crystalline Form 2 is not hydrated.
[0129] In some embodiments, lelipag in crystalline pattern 2 is characterized by having Figure 2An X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation.
[0130] In some embodiments, lelipag in crystalline pattern 2 is characterized by having an XRPD pattern with peaks at 4.1±0.2°2θ, 15.5±0.2°2θ, 16.9±0.2°2θ, 17.9±0.2°2θ, 22.8±0.2°2θ, 23.7±0.2°2θ, as measured using Cu Ka radiation. In some embodiments, lelipag in crystalline pattern 2 is characterized by having an XRPD pattern with peaks at 4.1±0.2°2θ, 15.5±0.2°2θ, and 16.9±0.2°2θ, as measured using Cu Ka radiation.
[0131] In some embodiments, lelipag in crystalline form 2 is further characterized as having Figure 8 In some embodiments, the crystalline form 2 of lelipag is further characterized as having a differential thermal analysis (TGA / DTA) thermogram showing weak endothermic and exothermic events from 81°C to 89°C and a broad endothermic event with an onset at about 124.7°C. In some embodiments, the crystalline form 2 of lelipag is further characterized as having an XRPD that converts to Form 1 upon heating. In some embodiments, the crystalline form 2 of lelipag is further characterized as a dimethyl sulfoxide solvate.
[0132] In some embodiments, lelipag in crystalline Pattern 2 is characterized as having:
[0133] and Figure 2 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; and
[0134] and Figure 8 Thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermograms substantially the same as shown in .
[0135] In some embodiments, lelipag in crystalline Pattern 2 is characterized as having:
[0136] An XRPD pattern having peaks at 4.1±0.2°2θ, 15.5±0.2°2θ, 16.9±0.2°2θ, 17.9±0.2°2θ, 22.8±0.2°2θ, 23.7±0.2°2θ, as measured using Cu Ka radiation; and a differential thermal analysis (TGA / DTA) thermogram showing weak endothermic and exothermic events from 81°C to 89°C and a broad endothermic event with an onset at about 124.7°C. In some embodiments, lelipag in crystalline pattern 2 is characterized as having:
[0137] an XRPD pattern having peaks at 4.1±0.2°2θ, 15.5±0.2°2θ, and 16.9±0.2°2θ, as measured using Cu Ka radiation; and a differential thermal analysis (TGA / DTA) thermogram showing weak endothermic and exothermic events from 81°C to 89°C and a broad endothermic event with an onset at about 124.7°C.
[0138] In some embodiments, lelipag in crystalline pattern 2 is characterized by having Figure 8 In some embodiments, the crystalline pattern 2 of lelipag is characterized by a DTA thermogram showing weak endothermic and exothermic events from 81°C to 89°C and a broad endothermic event with an onset at about 124.7°C. In some embodiments, the crystalline pattern 2 of lelipag is characterized by a DTA thermogram showing weak endothermic and exothermic events from 81°C to 89°C and a broad endothermic event with an onset at about 124.7°C and a peak at about 127.3°C. In some embodiments, the weak endothermic and exothermic events from 81°C to 89°C can be attributed to the recrystallization of crystalline pattern 2 and the formation of crystalline form 1. In some embodiments, the broad endothermic event with an onset at about 124.7°C can be attributed to crystalline form 1. In some embodiments, the crystalline pattern 2 of lelipag is characterized by an XRPD having a conversion to form 1 upon heating.
[0139] Crystalline Form 3 of Lelipag
[0140] In some embodiments, crystalline lelipag is crystalline Form 3 lelipag. In some embodiments, compositions comprising crystalline Form 3 lelipag are described herein. In some embodiments, crystalline Form 3 lelipag is referred to as crystalline Pattern 3 lelipag.
[0141] In some embodiments, lelipag in crystalline Form 3 is highly crystalline. In some embodiments, lelipag in crystalline Form 3 is partially crystalline. In some embodiments, lelipag in crystalline Form 3 has poor crystallinity.
[0142] In some embodiments, crystalline Form 3 of lelipag is recovered only from samples with dimethyl sulfoxide. In some embodiments, crystalline Form 3 of lelipag is solvated. In some embodiments, crystalline Form 3 of lelipag is a dimethyl sulfoxide solvate.
[0143] In some embodiments, crystalline Form 3 of lelipag is characterized as having Figure 3An X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation.
[0144] In some embodiments, lelipag in crystalline Form 3 is characterized by having an XRPD pattern with peaks at 3.6±0.2°2θ, 18.7±0.2°2θ, 22.2±0.2°2θ, 24.2±0.2°2θ, 24.3±0.2°2θ, as measured using Cu Ka radiation. In some embodiments, lelipag in crystalline Form 3 is characterized by having an XRPD pattern with peaks at 3.6±0.2°2θ, 18.7±0.2°2θ, and 22.2±0.2°2θ, as measured using Cu Ka radiation.
[0145] In some embodiments, crystalline Form 3 of lelipag is further characterized as having Fig. 9 In some embodiments, the crystalline form 3 of lelipag is further characterized as having a thermogravimetric analysis (TGA) trace showing a mass loss of 17.8% from the onset of heating to about 238°C. In some embodiments, the crystalline form 3 of lelipag is further characterized as having a differential thermal analysis (DTA) thermogram showing a sharp endothermic event with an onset at about 74.6°C. In some embodiments, the crystalline form 3 of lelipag is further characterized as a hydrate.
[0146] In some embodiments, crystalline Form 3 of lelipag is characterized as having Figure 3 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; and
[0147] and Fig. 9 Thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermograms substantially the same as shown in .
[0148] In some embodiments, crystalline Form 3 of lelipag is characterized as having:
[0149] having an XRPD pattern with peaks at 3.6±0.2°2θ, 18.7±0.2°2θ, 22.2±0.2°2θ, 24.2±0.2°2θ, 24.3±0.2°2θ as measured using Cu Ka radiation; and a TG trace showing a mass loss of 17.8% from the onset of heating to about 238°C; or a DTA thermogram showing a sharp endothermic event with an onset at about 74.6°C;
[0150] In some embodiments, crystalline Form 3 of lelipag is characterized by having: an XRPD pattern having peaks at 3.6±0.2°2θ, 18.7±0.2°2θ, and 22.2±0.2°2θ, as measured using Cu Ka radiation; and a TG trace showing a mass loss of 17.8% from the onset of heating to approximately 238°C; or a DTA thermogram showing a sharp endothermic event with an onset at about 74.6°C; or both.
[0151] In some embodiments, crystalline Form 3 of lelipag is characterized as having Fig. 9 In some embodiments, the crystalline form 3 of lelipag is characterized by having a TGA trace showing a mass loss of 17.8% from the onset of heating to about 238°C. In some embodiments, the crystalline form 3 of lelipag is characterized by having a DTA thermogram showing a sharp endothermic event with an onset at about 74.6°C. In some embodiments, the crystalline form 3 of lelipag is characterized by having a DTA thermogram showing a sharp endothermic event with an onset at about 74.6°C and a peak at about 78.9°C.
[0152] In some embodiments, crystalline Form 3 of lelipag has an XRPD pattern that exhibits unknown additional peaks.
[0153] Crystal Pattern 4 Rayleigh Pagle
[0154] In some embodiments, crystalline lelipag is crystalline Form 4 lelipag. In some embodiments, compositions comprising crystalline Form 4 lelipag are described herein.
[0155] In some embodiments, lelipag in crystalline pattern 4 is highly crystalline. In some embodiments, lelipag in crystalline pattern 4 is partially crystalline. In some embodiments, lelipag in crystalline pattern 4 has poor crystallinity.
[0156] In some embodiments, lelipag in crystalline Form 4 is anhydrous. In some embodiments, lelipag in crystalline Form 4 is not solvated. In some embodiments, lelipag in crystalline Form 4 is not hydrated.
[0157] In some embodiments, lelipag in crystalline Form 4 is recovered only from samples with water as the anti-solvent. In some embodiments, lelipag in crystalline Form 4 is solvated. In some embodiments, lelipag in crystalline Form 4 is a hydrate.
[0158] In some embodiments, lelipag in crystalline pattern 4 is characterized by having Figure 4An X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation.
[0159] In some embodiments, lelipag in crystalline pattern 4 is characterized by having an XRPD pattern with peaks at 15.0±0.2°2θ, 16.7±0.2°2θ, 18.0±0.2°2θ, 18.7±0.2°2θ, 18.9±0.2°2θ, as measured using Cu Ka radiation. In some embodiments, lelipag in crystalline pattern 4 is characterized by having an XRPD pattern with peaks at 15.0±0.2°2θ, 16.7±0.2°2θ, and 18.0±0.2°2θ, as measured using Cu Ka radiation.
[0160] In some embodiments, lelipag in crystalline pattern 4 is further characterized as having Fig.10 In some embodiments, the crystalline form 4 of lelipag is further characterized as having a differential thermal analysis (DTA) thermogram showing a broad endothermic event with an onset at about 29.0°C, a sharp endothermic event with an onset at about 127.8°C, or both. In some embodiments, the crystalline form 4 of lelipag is further characterized as having an XRPD that converts to Form 1 upon drying. In some embodiments, the crystalline form 4 of lelipag is further characterized as having an XRPD that converts to amorphous lelipag upon drying.
[0161] In some embodiments, lelipag in crystalline pattern 4 is characterized as having:
[0162] and Figure 4 an X-ray powder diffraction (XRPD) pattern substantially the same as shown in , as measured using Cu Ka radiation; and
[0163] and Fig.10 Thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermograms substantially the same as shown in .
[0164] In some embodiments, lelipag in crystalline pattern 4 is characterized as having:
[0165] an XRPD pattern having peaks at 15.0±0.2°2θ, 16.7±0.2°2θ, 18.0±0.2°2θ, 18.7±0.2°2θ, 18.9±0.2°2θ as measured using Cu Ka radiation; and a DTA thermogram showing a broad endothermic event with an onset at about 29.0°C and a sharp endothermic event with an onset at about 127.8°C.
[0166] In some embodiments, lelipag in crystalline pattern 4 is characterized as having:
[0167] an XRPD pattern having peaks at 15.0±0.2° 2θ, 16.7±0.2° 2θ, and 18.0±0.2° 2θ as measured using CuKα radiation; and
[0168] A DTA thermogram showing a broad endothermic event with an onset at about 29.0 °C and a sharp endothermic event with an onset at about 127.8 °C.
[0169] In some embodiments, lelipag in crystalline pattern 4 is characterized by having Fig.10 Thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermograms substantially the same as shown in . In some embodiments, the crystalline pattern 4 of Rayleipag is characterized as having a TG trace showing a significant mass loss (21.6%) before melting. In some embodiments, this mass loss can be attributed to the loss of residual solvent or water. In some embodiments, the crystalline pattern 4 of Rayleipag is characterized as having a DTA thermogram showing a broad endothermic event with an onset at about 29.0°C and a sharp endothermic event with an onset at about 127.8°C. In some embodiments, the crystalline pattern 4 of Rayleipag is characterized as having: a broad endothermic event showing an onset at about 29.0°C and a peak at about 64.0°C, and a DTA thermogram showing a sharp endothermic event with an onset at about 127.8°C and a peak at about 130.4°C. In some embodiments, a broad endothermic event with an onset at about 29.0°C can be attributed to the loss of residual solvent or water and the recrystallization of crystalline pattern 4 and the formation of crystalline form 1. In some embodiments, a sharp endothermic event with an onset at about 127.8°C can be attributed to crystalline form 1. In some embodiments, lelipag in crystalline pattern 4 is characterized as having an XRPD that converts to form 1 upon drying. In some embodiments, lelipag in crystalline pattern 4 is characterized as having an XRPD that converts to form 1 upon drying in air under ambient conditions. In some embodiments, lelipag in crystalline pattern 4 is characterized as having an XRPD that converts to amorphous lelipag upon drying.
[0170] Rayleigh Pag's Salt
[0171] In one aspect, pharmaceutically acceptable salts of lelipag are prepared, including solvates, hydrates, and unsolvated forms thereof.
[0172] It should be understood that reference to pharmaceutically acceptable salts includes solvent addition forms. In some embodiments, solvates contain stoichiometric or non-stoichiometric amounts of solvents and are formed with pharmaceutically acceptable solvents such as water, ethanol, etc. during the crystallization process. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein and crystalline forms thereof are conveniently prepared or formed during the process described herein. In addition, compounds provided herein and crystalline forms thereof are optionally present in non-solvated and solvated forms.
[0173] As used herein, "pharmaceutically acceptable" refers to a material such as a carrier or diluent that does not abrogate the biological activity or properties of the compound and is relatively nontoxic, i.e., the material can be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any component of a composition containing the material.
[0174] The term "pharmaceutically acceptable salt" refers to a form of a therapeutically active agent that consists of a cationic form of the therapeutically active agent in combination with a suitable anion, or in alternative embodiments, consists of an anionic form of the therapeutically active agent in combination with a suitable cation. Handbook of Pharmaceutical Salts: Properties, Selection and Use. International Union of Pure and Applied Chemistry, Wiley-VCH 2002. SM Berge, LD Bigley, DC Monkhouse, J. Pharm. Sci. 1977, 66, 1-19. PH Stahl and CG Wermuth, editors, Handbook of Pharmaceutical Salts: Properties, Selection and Use, Weinheim / Zürich: Wiley-VCH / VHCA, 2002. Pharmaceutically acceptable salts are generally more soluble and dissolve more rapidly in gastric and intestinal fluids than non-ionic species, and are therefore useful in solid dosage forms. Furthermore, because their solubility is often a function of pH, selective dissolution in one or another part of the digestive tract is possible, and this ability can be manipulated as an aspect of delayed and sustained release behavior. Furthermore, because salt-forming molecules can equilibrate with the neutral form, passage through biological membranes can be tuned.
[0175] In some embodiments, pharmaceutically acceptable salts are obtained by reacting the compounds disclosed herein with an acid. In some embodiments, the compounds disclosed herein (i.e., free alkali form) are alkaline and react with organic or inorganic acids. Inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and metaphosphoric acid. Organic acids include, but are not limited to, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid (L), aspartic acid (L), benzenesulfonic acid, benzoic acid, camphoric acid (+), camphor-10-sulfonic acid (+), caprylic acid (decanoic acid), caprylic acid (caproic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclohexanesulfamic acid, dodecylsulfuric acid, 1,2-ethanedisulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, Gentisic acid, glucoheptonic acid (D), gluconic acid (D), glucuronic acid (D), glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid (DL), lactobionic acid, lauric acid, maleic acid, malic acid (-L), malonic acid, mandelic acid (DL), methanesulfonic acid, 1,5-naphthalene disulfonic acid, 2-naphthalenesulfonic acid, nicotinic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, pyroglutamic acid (-L), salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid (+L), thiocyanic acid, toluenesulfonic acid (p) and undecylenic acid.
[0176] In some embodiments, a pharmaceutically acceptable salt is obtained by reacting lelipag with a base. In such cases, the acidic protons of lelipag are replaced by metal ions (e.g., lithium ions, sodium ions, potassium ions, magnesium ions, calcium ions, or aluminum ions). Acceptable inorganic bases for forming salts with compounds including acidic protons include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydroxide, lithium hydroxide, and the like.
[0177] In some cases, lelipag is coordinated with an organic base such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, meglumine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, lelipag forms salts with amino acids such as, but not limited to, arginine, lysine, etc.
[0178] In some embodiments, lelipag is prepared as a sodium salt, a calcium salt, a potassium salt, a magnesium salt, a meglumine salt, an N-methylglucamine salt, or an ammonium salt.
[0179] In another aspect, cocrystals of lelipag, including solvates, hydrates and unsolvated forms thereof, are prepared. Salts are formed by complete transfer of a proton from one compound to another. Salts and cocrystals can be distinguished based on the transfer of a proton from an acid to a base. Complete transfer of a proton occurs between the acid-base pair, however, no proton transfer occurs during cocrystal formation.
[0180] Therapeutic agents (such as lelipag) administered to mammals (such as humans) must be prepared in accordance with regulatory guidelines. Such government-mandated guidelines are referred to as Good Manufacturing Practices (GMP). GMP guidelines outline acceptable levels of contamination for active therapeutic agents, such as, for example, the amount of residual solvents in the final product. Preferred solvents are those suitable for use in GMP facilities and consistent with industrial safety issues. The categories of solvents are defined in, for example, the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), "Impurities: Guidelines for Residual Solvents, Q3C (R3), (November 2005).
[0181] Solvents are divided into three categories. Class 1 solvents are toxic and are to be avoided. Class 2 solvents are solvents that are restricted in use during the manufacture of therapeutic agents. Class 3 solvents are solvents that have low toxicity potential and pose a lower risk to human health. Data for Class 3 solvents show that they are less toxic in acute or short-term studies and are negative in genotoxicity studies.
[0182] Class 1 solvents to avoid include: benzene; carbon tetrachloride; 1,2-dichloroethane; 1,1-dichloroethylene and 1,1,1-trichloroethane.
[0183] Examples of Class 2 solvents are acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethylene, dichloromethane, 1,2-dimethoxyethane, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methyl butyl ketone, methylcyclohexane, N-methylpyrrolidine, nitromethane, pyridine, sulfolane, tetralin, toluene, 1,1,2-trichloroethylene, and xylene.
[0184] Class 3 solvents with low toxicity include: acetic acid, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, methyl tert-butyl ether (MTBE), isopropylbenzene, dimethyl sulfoxide, ethanol, ethyl acetate, ethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate and tetrahydrofuran.
[0185] Residual solvents in active pharmaceutical ingredients (APIs) originate from the preparation of the APIs. In some cases, the solvents are not completely removed by actual manufacturing techniques. Appropriate selection of solvents for synthesizing APIs can improve yield or determine characteristics (such as crystal form, purity, and solubility). Therefore, solvents are key parameters in the synthesis process.
[0186] In some embodiments, the composition comprising lelipag or a pharmaceutically acceptable salt thereof comprises an organic solvent. In some embodiments, the composition comprising lelipag or a pharmaceutically acceptable salt thereof comprises a residual amount of an organic solvent.
[0187] In some embodiments, the composition comprising lelipag or a pharmaceutically acceptable salt thereof comprises a residual amount of Class 3 solvents. In some embodiments, the Class 3 solvents are selected from acetic acid, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, methyl tert-butyl ether, isopropylbenzene, dimethyl sulfoxide, ethanol, ethyl acetate, ethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate and tetrahydrofuran. In some embodiments, the Class 3 solvents are selected from ethyl acetate, isopropyl acetate, methyl tert-butyl ether, heptane, isopropanol and ethanol.
[0188] In some embodiments, the composition comprising lelipag or a pharmaceutically acceptable salt thereof includes a detectable amount of an organic solvent. In some embodiments, the pharmaceutically acceptable salt of lelipag is a tosylate salt (i.e., lelipag-tosyl). In some embodiments, the organic solvent is a Class 3 solvent (i.e., 1-butanol).
[0189] In other embodiments are compositions comprising lelipag or a pharmaceutically acceptable salt thereof, wherein the composition comprises less than about 1% of a detectable amount of solvent, wherein the solvent is selected from acetone, 1,2-dimethoxyethane, acetonitrile, ethyl acetate, tetrahydrofuran, methanol, ethanol, heptane, and 2-propanol. In further embodiments are compositions comprising lelipag or a pharmaceutically acceptable salt thereof, wherein the composition comprises less than about 5000 ppm of a detectable amount of solvent. In yet further embodiments are compositions comprising lelipag, wherein the detectable amount of solvent is less than about 5000 ppm, less than about 4000 ppm, less than about 3000 ppm, less than about 2000 ppm, less than about 1000 ppm, less than about 500 ppm, or less than about 100 ppm.
[0190] definition
[0191] Unless otherwise stated, the following terms used in this application have the definitions given below. The use of the term "including" as well as other forms, such as "include", "includes", and "included" is not limiting. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0192] With respect to a formulation, composition or ingredient as used herein, the term "acceptable" means having no persistent detrimental effect on the general health of the subject being treated.
[0193] As used herein, the term "modulate" means to interact directly or indirectly with a target so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, inhibit the activity of the target, limit the activity of the target, or extend the activity of the target.
[0194] As used herein, the term "modulator" refers to a molecule that interacts directly or indirectly with a target. Interactions include, but are not limited to, interactions of agonists, partial agonists, inverse agonists, antagonists, degraders, or combinations thereof. In some embodiments, the modulator is an agonist.
[0195] As used herein, the terms "administer", "administering", "administration", etc. refer to methods that can be used to enable the delivery of a compound or composition to a desired biological site of action. These methods include, but are not limited to, oral routes, intraduodenal routes, parenteral injections (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular or infusion) and topical administration. Those skilled in the art are familiar with administration techniques that can be used with the compounds and methods described herein. In some embodiments, the compounds and compositions described herein are administered orally. In some embodiments, the compounds and compositions described herein are administered intranasally or by inhalation.
[0196] The terms "co-administered," "co-administered," and the like as used herein are intended to encompass administration of selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different routes of administration, or at the same or different times.
[0197] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of an administered agent or compound that will alleviate to some extent one or more symptoms of the disease or condition being treated. Results include reduction and / or alleviation of signs, symptoms, or causes of a disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound as disclosed herein required to provide a clinically significant reduction in disease symptoms. A suitable "effective" amount in any individual case is optionally determined using techniques such as dose escalation studies.
[0198] As used herein, the terms "enhance" or "enhancing" mean to increase or prolong, either in potency or duration, a desired effect. Thus, with respect to enhancing the effect of a therapeutic agent, the term "enhancing" refers to the ability to increase or prolong, either in potency or duration, the effect of another therapeutic agent on a system. As used herein, an "enhancing-effective amount" refers to an amount sufficient to enhance the effect of another therapeutic agent in a desired system.
[0199] The term "subject" or "patient" encompasses mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates (such as chimpanzees and other apes and monkey species); farm animals such as cattle, horses, sheep, goats, pigs; livestock such as rabbits, dogs and cats; laboratory animals, including rodents such as rats, mice and guinea pigs, etc. In one aspect, the mammal is a human.
[0200] As used herein, the terms "treat," "treating," or "treatment" include prophylactically and / or therapeutically alleviating, alleviating or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting a disease or condition, such as arresting the development of a disease or condition, relieving a disease or condition, causing regression of a disease or condition, alleviating the conditions caused by a disease or condition, or arresting the symptoms of a disease or condition.
[0201] The term "about" means within the range of statistically significant values, such as described concentration range, time range, molecular weight, particle size, temperature or pH. Such a range can be within the order of magnitude of the indicated value or range, typically within 10%, more typically within 5%, and even more typically within 3%. Sometimes, such a range can be within the experimental error of a typical standard method for measuring and / or determining a given value or range. The permissible variations covered by the term "about" will depend on the specific system under study and can be easily understood by those of ordinary skill in the art. Whenever a range is described in this application, each integer within the range is also considered to be an embodiment of the present invention.
[0202] The term "substantially the same" as used herein for reference to a figure is intended to mean that the figure is considered to represent the type and kind of characteristic data obtained by those skilled in the art in view of acceptable deviations in the art. Such deviations may be caused by factors related to changes in sample size, sample preparation, the specific instrument used, operating conditions, and other experimental conditions known in the art. For example, it will be appreciated by those skilled in the art that the endothermic onset temperature and peak temperature measured by differential scanning calorimetry (DSC) may vary significantly due to differences in experiments. For example, those skilled in the art can easily identify whether two X-ray diffraction patterns or two DSC thermograms are substantially the same. In some embodiments, when the characteristic peaks of two X-ray diffraction patterns present a difference of no more than ± 0.2 ° 2θ, the X-ray diffraction patterns are considered to be substantially the same.
[0203] Pharmaceutical composition
[0204] In some embodiments, the compounds and solid forms described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of active compounds into pharmaceutically used preparations. Appropriate formulations depend on the selected route of administration. An overview of the pharmaceutical compositions described herein can be found in, for example, Remington: The Science and Practice of Pharmacy, 19th edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th edition. (Lippincott Williams & Wilkins 1999), which are incorporated herein by reference for such disclosures.
[0205] In some embodiments, the compounds and solid forms described herein are administered alone or in combination with a pharmaceutically acceptable carrier, excipient, or diluent in a pharmaceutical composition. Administration of the compounds and compositions described herein can be achieved by any method that enables delivery of the compound to the site of action.
[0206] In some embodiments, pharmaceutical compositions suitable for oral administration are presented as discrete units (such as capsules, sachets, or tablets containing a predetermined amount of active ingredient); powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; or oil-in-water liquid emulsions or water-in-oil liquid emulsions. In some embodiments, the active ingredient is presented as a bolus, electuary, or paste.
[0207] Pharmaceutical compositions that can be used orally include tablets, push-fit capsules made of gelatin, and soft sealed capsules made of gelatin and plasticizers such as glycerol or sorbitol. Tablets can be prepared by compression or molding (optionally with one or more auxiliary ingredients). Compressed tablets can be prepared by compressing an active ingredient (such as a powder or granules) in a free-flowing form in a suitable machine, the active ingredient optionally mixed with a binder, an inert diluent or lubricant, a surfactant or a dispersant. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. In some embodiments, the tablets are coated or scored and formulated so as to provide a slow release or controlled release of the active ingredient therein. All preparations for oral administration should have a dosage suitable for such administration. Push-fit capsules can contain active ingredients mixed with fillers (such as lactose), binders (such as starches) and / or lubricants (such as talc or magnesium stearate) and optionally stabilizers. In soft capsules, the active compound can be dissolved or suspended in a suitable liquid (such as fatty oil, liquid paraffin or liquid polyethylene glycol). In some embodiments, a stabilizer is added. The dragee core is provided with a suitable coating. For this purpose, concentrated sugar solution can be used, which can optionally contain gum arabic, talcum, polyvinyl pyrrolidone, carbopol gel (carbopol gel), polyethylene glycol and / or titanium dioxide, lacquer solution and suitable organic solvent or solvent mixture. Dye or pigment can be added to tablet or dragee coating for identification or characterization of the different combinations of active compound dosage.
[0208] It should be understood that in addition to the ingredients particularly mentioned above, the compounds and compositions described herein may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
[0209] In some embodiments, the formulations described herein are suitable for oral or nasal inhalation. The inhalable formulations described herein include formulations that allow for rapid delivery of lelipag to the circulatory system and / or target organs (eg, lungs) of a mammal in need thereof.
[0210] In certain embodiments, the inhalable formulation is in the form of a dry powder. In some embodiments, the dry powder is delivered with a propellant. In some embodiments, the dry powder is delivered without a propellant. In some cases, the dry powder is a single-phase solid particle blend. In some cases, when driven, the dry powder is a two-phase gas-solid system in which the dry powder is dispersed in the air.
[0211] In some embodiments, the dry powder contains at least one pharmaceutically acceptable excipient selected from the group consisting of a pH modifier, a tonicity agent, a propellant, a preservative, and a surfactant.
[0212] In some embodiments, the dry powder comprises micronized and / or nanosized prostacyclin (IP) receptor agonist particles blended with larger carrier particles that prevent aggregation. The excipients and / or carriers in the dry powder are endogenous to the lung and are easily metabolized or cleared.
[0213] In some cases, dry powder contains lactose as a carrier. In some cases, dry powder comprises starch, mannitol or glucose as a carrier. In some cases, dry powder is formulated as a liposome comprising phospholipids (e.g., phosphatidylcholine), cholesterol, etc. The carrier particles have low hygroscopicity (e.g., lactose) to prevent aggregation or agglomeration due to moisture absorption.
[0214] In some cases, a dry powder inhalable formulation described herein comprises nanoparticles of lelipag. In some cases, a dry powder inhalable formulation described herein comprises crystalline particles. In some embodiments, a dry powder inhalable formulation described herein comprises amorphous particles.
[0215] In some embodiments, the inhalable formulation is administered with a dry powder inhaler (DPI) or a metered dose inhaler (MDI).
[0216] In some cases, the dry powder inhalable formulations described herein are administered with a dry powder inhaler (DPI). The drug is typically loaded into the chamber of the inhaler as a capsule and then delivered by the patient's inhalation, preferably a deep and forceful inhalation.
[0217] In some embodiments, the inhalable formulations described herein are administered with a metered dose inhaler (MDI). In some embodiments, the inhalable formulations described herein include a propellant, and a pressurized aerosol is used to pressurize the packaging for administering lelipag. In some embodiments, the metered dose inhaler includes three main parts: a can, a metering valve, and an actuator. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. In some cases, after depressing the top of the can and actuating the MDI, a single metered dose containing the drug in the propellant is released, generating an aerosol that is then inhaled by the patient.
[0218] In some cases, the dry powder inhalable formulations described herein are administered with a puffer. The dry powder is placed in the puffer and the puffer is squeezed. A portion of the powder is ejected from the nozzle into the air and inhaled. By way of example only, capsules and cartridges such as gelatin for use in an inhaler or insufflator can be formulated to contain the dry powder formulations described herein.
[0219] Dosage and treatment regimen
[0220] In one embodiment, the compounds disclosed herein and solid forms or pharmaceutically acceptable salts thereof are used to prepare a medicament for treating a disease or condition in a mammal that would benefit from the regulation of prostacyclin (IP) receptor agonist activity. The method for treating any disease or condition described herein in a mammal in need of such treatment involves administering a pharmaceutical composition to the mammal in a therapeutically effective amount, the pharmaceutical composition comprising at least one compound disclosed herein or a pharmaceutically acceptable salt thereof, an active metabolite, a prodrug or a pharmaceutically acceptable solvate thereof.
[0221] In certain embodiments, compositions containing compounds described herein and solid forms are used for preventive and / or therapeutic treatment. In certain therapeutic applications, compositions are administered to patients who have already suffered from a disease or condition in an amount sufficient to cure or at least partially prevent at least one symptom of a disease or condition. The effective amount for this purpose depends on the severity and course of the disease or condition, previous treatment, the patient's health, body weight, and the response to the drug and the judgment of the attending physician. The therapeutically effective amount is optionally determined by methods including but not limited to dose escalation and / or dosage range clinical trials.
[0222] The amount of a given agent corresponding to such an amount varies depending on factors such as the specific compound, the disease condition and its severity, the characteristics of the subject or host in need of treatment (e.g., weight, sex), but will still be determined according to the specific circumstances relevant to the case, including, for example, the specific agent administered, the route of administration, the condition being treated, and the subject or host being treated.
[0223] However, in general, the dosage adopted for adult treatment is typically within the range of 0.01 mg-0.6 mg per day. In one embodiment, the desired dosage is conveniently presented in a single dose or in divided doses (e.g., as twice or more sub-doses per day) administered simultaneously or at appropriate intervals. In some embodiments, based on many variables about individual treatment regimens, the daily dose or the amount of active agent in the dosage form is lower or higher than the scope indicated herein. In different embodiments, daily dose and unit dose are changed according to many variables, including but not limited to: the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition to be treated, and the judgment of the physician.
[0224] In any of the above aspects are further embodiments in which an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof is: (a) administered systemically to a mammal; and / or (b) administered orally to a mammal; and / or (c) administered to a mammal by inhalation.
[0225] In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered in an amount equivalent to about 0.01 mg, about 0.02 mg, about 0.03 mg, about 0.04 mg, about 0.05 mg, about 0.06 mg, about 0.07 mg, about 0.08 mg, about 0.09 mg, about 0.1 mg, about 0.12 mg, about 0.13 mg, about 0.14 mg, about 0.15 mg, about 0.16 mg, about 0.17 mg, about 0.18 mg, about 0.19 mg, about 0.2 mg, about 0.21 mg, about 0.22 mg, about 0.23 mg, about 0.24 mg, about 0.25 mg, about 0.26 mg, about 0.27 mg, about 0.28 mg, about 0.29 mg, about 0. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered in an amount of 0.05 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.10 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.15 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.20 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.25 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.30 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.35 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.40 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.45 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.5 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.55 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.60 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.65 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.70 mg per day.In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.75 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.80 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.85 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.9 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 0.95 mg per day. In some embodiments, lelipag or a pharmaceutically acceptable salt thereof is administered at 1 mg per day. In some embodiments, the dosage is administered once a day. In some embodiments, the dosage is administered twice a day.
[0226] Other embodiments and uses will be apparent to those skilled in the art in view of this disclosure.The following examples are provided merely as illustrations of the various embodiments and should not be construed as limiting the invention in any way.
[0227] Example
[0228] abbreviation:
[0229] HPLC-UV = High Performance Liquid Chromatography - Ultraviolet Detection
[0230] NMR = Nuclear Magnetic Resonance
[0231] RH = relative humidity
[0232] v / v = volume ratio
[0233] w / w = weight ratio
[0234] 2-methyl THF=2-methyltetrahydrofuran
[0235] tBME = tert-butyl methyl ether
[0236] t-BuOH = tert-butyl alcohol
[0237] DCM = dichloromethane, dichloromethane (methylene chloride)
[0238] DIPE = diisopropyl ether
[0239] DMA=N,N-dimethylacetamide
[0240] DMF=N,N-dimethylformamide
[0241] DMSO = dimethyl sulfoxide
[0242] DIPE = diisopropyl ether
[0243] EtOAc = Ethyl acetate
[0244] EtOH = ethanol
[0245] iPrAc=isopropyl acetate
[0246] MEK = Methyl Ethyl Ketone
[0247] MeOH = methanol
[0248] MIBK = Methyl Isobutyl Ketone
[0249] NMP = N-methyl-2-pyrrolidone
[0250] THF = Tetrahydrofuran
[0251] tol = toluene
[0252] mL = milliliters
[0253] μL = microliter
[0254] The following examples are provided for illustrative purposes only and do not limit the scope of the claims provided herein.
[0255] Example 1: Preparation of Lelipag
[0256] The preparation of lelipag has been previously described (see, WO 2009 / 117095, US 8,895,776, US 10,668,033, and US 2020 / 0375930, each of which is herein incorporated by reference in its entirety).
[0257] Example 2: Preparation of amorphous lelipag from crystalline form 1
[0258] Example 2a: Attempt 1
[0259] To prepare amorphous material for primary polymorph screening, 1.2 g of lelipag was dissolved in 336 mL of 1,4-dioxane and divided into 24 vials (approximately 50 mg of lelipag per sample). The vials of solution were frozen at -50°C before freeze drying overnight. An aliquot of the freeze-dried solid was analyzed by XRPD and confirmed to be poorly crystalline Form 1.
[0260] Example 2b: Attempt 2
[0261] The solid from Example 2a was redissolved in 100 mL of methanol and the solvent removed via rotary evaporation. An aliquot of the solid was analyzed by XRPD and confirmed to be Form 1.
[0262] Example 2c: Attempt 3
[0263] The solid from Example 2b was redissolved in 100 mL DCM and the solvent removed via rotary evaporation. An aliquot of the solid was analyzed by XRPD and confirmed to be Form 1.
[0264] Example 2d: Attempt 4
[0265] The solid from Example 2c was dissolved in 240 mL of tert-butyl alcohol and the solution was divided between 24 vials and freeze dried as described in Example 2a. An aliquot of the solid was analyzed by XRPD and confirmed to be Form 1.
[0266] Example 2e: Attempt 5
[0267] The solid from one vial of Example 2d was dissolved in 200 μL DCM, followed by a batch addition of 2 mL of heptane as an anti-solvent to precipitate the solid. A small amount of precipitation was noted, which stuck to the side of the vial. The solution was decanted and a spatula was used to remove the solid for XRPD analysis. Form 1 was observed.
[0268] Example 2f: Attempt 6
[0269] All solids from Examples 2d and 2e were combined and redissolved in 336 mL 1,4-dioxane, then divided into 24 vials and freeze-dried as described in Example 2a. An aliquot of the solid was analyzed by XRPD and confirmed to be amorphous lelipag. This was used for major polymorph screening.
[0270] Example 2g: Attempt 7
[0271] To generate additional amorphous material, 300 mg of lelipag was dissolved in 84 mL 1,4-dioxane, aliquoted between 6 vials and lyophilized as before. An aliquot of the solid was analyzed by XRPD and confirmed to be the new Form 2.
[0272] Example 2i: Attempt 8
[0273] Six vials of lyophilized lelipag from Example 2g were each dissolved in 16 mL 1,4-dioxane and lyophilized as before. An aliquot of the solid was analyzed by XRPD and confirmed to be Form 2. The sample was dried under vacuum at 40°C for approximately 21 h, and an aliquot of the solid was analyzed by XRPD, and Form 2 was found to remain. It was analyzed by TGA / DTA.
[0274] Summary of results
[0275] As seen in attempts 1 to 8, rapid evaporation of MeOH and DCM, addition of heptane to the DCM solution, and lyophilization of the t-BuOH and 1,4-dioxane solution produced Form 1. However, amorphous lelipag was successfully prepared via lyophilization of a more dilute lelipag solution in 1,4-dioxane.
[0276] Amorphous material was used for the major polymorph screen to eliminate the presence of any potential seed material in the experiment.
[0277] Example 3: Study on the Solvent Solubility of Lelipag
[0278] To prepare amorphous material for solubility testing, 330 mg of lelipag was dissolved in 33 mL of tert-butyl alcohol (mild heating was applied via an air heat gun) and then divided equally into 33 vials (approximately 10 mg of lelipag per sample). The vials of solution were frozen at -50 ° C before freeze drying overnight. One vial of solid was analyzed by XRPD to confirm that lelipag had been rendered amorphous. However, as in Example 2g, poorly crystalline Form 2 was observed.
[0279] The 32 solvents and solvent systems were added to 32 x 10 mg of lyophilized lelipampug in 50 μL aliquots for the first 300 μL or until complete dissolution was noted. If complete dissolution was not observed, 100 μL aliquots were added thereafter until the total solvent was 1 mL. Between each addition, the mixture was manually shaken for a few seconds, and if complete dissolution was not evident, the mixture was heated to about 40°C and checked again.
[0280] In the case where complete dissolution occurred, the solvent was allowed to evaporate at ambient temperature. In the case where complete dissolution was not observed, the solid was isolated via centrifugal filtration. The recovered solid was analyzed by XRPD.
[0281] The results from the solvent screening are summarized in Table 1.
[0282] Table 1. Solvent solubility results of amorphous* lelipag
[0283]
[0284] (H) = heated to 40°C; * poor crystallization; Preferred orientation
[0285] Poorly crystalline lelipipag was found to be soluble in 29 of 32 solvent systems at concentrations of 10 mg / mL or greater.
[0286] No solids were obtained from 1-butanol, benzyl alcohol or N-methylpyrrolidone.
[0287] The new pattern Form 3 was generated from the solid recovered upon evaporation of dimethyl sulfoxide.
[0288] The poorly crystalline form 1 was recovered upon evaporation of 1,1-methylacetal, acetone and water.
[0289] The remaining solvent system produced Form 1.
[0290] As described herein, the following samples produced crystalline Form 1 of lelipag in a preferred orientation: 1,4-dioxane, 1-propanol, 2-ethoxyethanol, 2-methyltetrahydrofuran, 2-methyl-1-propanol, ethanol / water (93:7% v / v), ethanol / water (98.5:1.5% v / v), acetonitrile, butyl acetate, ethanol, ethyl acetate, methanol, methyl ethyl ketone, methyl isobutyl ketone, methyl tert-butyl ether, tetrahydrofuran, and toluene.
[0291] Example 4: Polymorph Screening of Lelipag
[0292] Using the amorphous material prepared from Example 2f above, different solvent systems were added to attempts to form slurries (where possible). The slurries / solutions were thermocycled (with stirring) between ambient temperature and 40°C (4 hour cycles) for 72h (no heating / cooling rates specified).
[0293] Any solid material remaining after the temperature cycling was isolated by centrifugal filtration and the isolated material was analyzed by XRPD.The solids were dried in a vacuum oven at 40°C for 2 h and then analyzed again by XRPD.
[0294] The separated mother liquor was divided into 3 equal parts and the following experiments were performed:
[0295] (a) Evaporation at ambient temperature.
[0296] (b) Rapid cooling initially at 5°C and then, if no solids were observed, at -20°C.
[0297] (c) Addition of antisolvent: 2 mL of antisolvent was added and the sample was left overnight at ambient temperature.
[0298] In the event that no solids were recovered after thermal cycling, the resulting slurry after addition of anti-solvent was thermal cycled as described above. Any solids recovered were analyzed by XRPD, dried as described above and analyzed again by XRPD. TGA / DTA and NMR analysis were performed on all samples where the amount of material permitted.
[0299] The results from the polymorph screening are shown in Tables 2 and 3.
[0300] Table 2. Solvents used in the polymorph screening of lelipag
[0301]
[0302] * Anti-solvent was added and the resulting solution / slurry was thermal cycled as before
[0303] Table 3. XRPD results of solids obtained from polymorph screening of lelipag.
[0304]
[0305]
[0306] *Poor crystallinity; **Antisolvent added; Am. = amorphous; ns = no solid recovered; Preferred orientation
[0307] Thermal Cycle
[0308] After thermal cycling, only Form 1 was recovered (or amorphous material containing a peak of Form 1), with the exception of N,N-dimethylacetamide / water and N-methyl-2-pyrrolidone / water mixtures (which produced amorphous material). Fig.14f and Figure 14g All Form 1 solids appeared to be highly crystalline, with a slight decrease in crystallinity noted in the solids recovered from N,N-dimethylformamide, methyl tert-butyl ether, and water.
[0309] When dried, Form 1 was recovered in all samples. Several solids that were amorphous / mostly amorphous when wet dried to Form 1, such as solids from 2-methyl-tetrahydrofuran, benzyl alcohol, toluene, N,N-dimethylacetamide / water, and N-methyl-2-pyrrolidone / water.
[0310] evaporation
[0311] All samples that produced solids upon evaporation provided Form 1, except dimethyl sulfoxide, which provided Form 3.
[0312] Rapid Cooling
[0313] Only 2-ethoxyethanol (Form 1) and acetone (amorphous with some Form 1 peaks) gave solids upon rapid cooling.
[0314] Antisolvent addition
[0315] Solids isolated from 1,4-dioxane / heptane, 1-propanol / heptane, 2-ethoxyethanol / heptane, dimethyl sulfoxide / water, methyl isobutyl ketone / heptane, N,N-dimethylformamide / water, methyl tert-butyl ether / heptane, tetrahydrofuran / heptane, toluene / heptane, and chloroform / heptane provided Form 1. Amorphous material was obtained from 2-methyl-tetrahydrofuran / heptane, ethanol / water, acetone / heptane, acetonitrile / water, butyl acetate / heptane, ethanol / heptane, and ethyl acetate / heptane.
[0316] When water was added as an anti-solvent, a new sample (Sample 4) was recovered from N,N-dimethylacetamide and N-methyl-2-pyrrolidone. Upon drying, Form 1 was produced from Sample 4. For analysis of Sample 4, another sample was prepared from N-methyl-2-pyrrolidone / water.
[0317] The manner in which the sample is prepared may affect the relative intensities of the peaks. In other words, many sample preparations of crystalline Form 1 exhibited preferred orientations, including:
[0318] Samples prepared by thermal cycling in acetone;
[0319] All samples prepared by solvent evaporation; and
[0320] • Samples prepared by adding anti-solvents 1-propanol / heptane, 2-ethoxyethanol / heptane, and methyl isobutyl ketone / heptane.
[0321] Example 5: X-ray powder diffraction (XRPD)
[0322] Although the following diffractometer is used, other types of diffractometers may be used. In addition, other wavelengths may be used and converted to Cu Ka. In some embodiments, synchrotron radiation X-ray powder diffraction (SR-XRPD) may be used to characterize the crystalline form.
[0323] "Characteristic peaks" are a subset of observed peaks to the extent they are present and are used to distinguish one crystalline polymorph from another (a polymorph is a crystalline form having the same chemical composition). Characteristic peaks are determined by evaluating which observed peaks, if any, are present in one crystalline polymorph of a compound within ±0.2° 2θ for all other known crystalline polymorphs of the compound.
[0324] XRPD analysis was performed on a PANalytical X'pert pro with a PIXcel detector (128 channels), scanning the samples between 3 and 35° 2θ. The material was gently ground to release any agglomerates and loaded onto a porous plate with Kapton or Mylar polymer film to support the sample. The porous plate was then placed in the diffractometer and the sample was analyzed using Cu K radiation (α1 α1:α2 ratio = 0.5) was analyzed using a 40 kV / 40 mA generator setting. Data were visualized and images were generated using HighScore Plus 4.7 desktop application (PANalytical, 2017).
[0325] For samples with only one XRPD pattern and no other means to assess whether the sample provides a good approximation of the powder average, the peak table contains data identified only as "significant peaks". These peaks are a subset of the entire observed peak list. Significant peaks are selected from the observed peaks by identifying preferably non-overlapping, low-angle peaks (with strong intensity).
[0326] Characterization of Crystalline Form 1 of Lelipag
[0327] The X-ray powder diffraction pattern of lelipag in crystalline form 1 is Figure 1 Representative peaks include those listed in the following table:
[0328] Angle 2θ(°) Relative strength [%] 8.8 17.56 11.7 72.81 16.1 27.95 16.2 70.90 16.7 100.00 18.8 91.82 20.4 44.58 20.5 54.04 21.3 74.49 24.5 78.44 25.8 41.18 33.8 16.18
[0329] Characteristic peaks of lelipag in crystalline form 1 may include 8.8±0.2°2θ, 11.7±0.2°2θ, 16.2±0.2°2θ, 21.3±0.2°2θ, and 33.8±0.2°2θ. Characteristic peaks of lelipag in crystalline form 1 may include peaks at 8.8±0.2°2θ, 11.7±0.2°2θ, and 16.2±0.2°2θ.
[0330] The manner in which the sample is prepared can affect the relative intensities of the peaks. For example, all samples prepared via solvent evaporation, as described in Example 4, as well as many samples prepared by other methods, exhibited a preferred orientation. Additional X-ray powder diffraction patterns of lelipag, obtained from isolated crystalline Form 1 throughout the Examples described herein, are shown at Figures 12a to 12f , Figures 13a to 13e , Figures 14a to 14e , Figures 15a to 15c , Fig.16 , Figures 17a to 17bThese additional patterns show the variations in the XRPD patterns of lelipag in crystalline Form 1 obtained throughout the Examples herein.
[0331] If multiple diffraction patterns are available, an assessment of particle statistics (PS) and / or preferred orientation (PO) is possible. The consistency of relative intensity among the XRPD patterns from multiple diffractometers indicates good orientation statistics. Alternatively, the observed XRPD pattern can be compared with the XRPD pattern calculated based on the single crystal structure (if available). A two-dimensional scattering pattern using an area detector can also be used to assess PS / PO. If the effects of both PS and PO are determined to be negligible, the XRPD pattern is representative of the powder average intensity of the sample, and significant peaks can be identified as "representative peaks".
[0332] The term "preferred orientation" as used herein refers to an extreme case of non-random distribution of crystallites in a solid state form. In XRPD, an ideal sample is uniform and the crystallites are randomly distributed in the bulk solid. In a truly random sample, each possible reflection from a given set of planes will have an equal number of crystallites contributing to it. However, this is not the case when the solid state form is in a preferred orientation. Therefore, comparing the intensity between a random orientation diffraction pattern and a preferred orientation diffraction pattern can look completely different. Quantitative analysis that depends on intensity ratios is greatly distorted by preferred orientation.
[0333] Characterization of Crystallization Pattern 2 of Relelipimer
[0334] The X-ray powder diffraction pattern of lelipagulin in crystalline form 2 is Figure 2 Representative peaks include those listed in the following table:
[0335] Angle 2θ(°) Relative strength [%] 4.1 31.97 15.5 30.35 16.9 95.99 17.9 100.00 18.8 54.17 21.6 57.14 22.8 74.31 23.7 66.02
[0336] Sample 2 was recovered from tert-butanol and 1,4-dioxane only after lyophilization and in a poorly crystalline form.
[0337] Form 2 transforms into Form 1 upon heating.
[0338] Characterization of Crystalline Form 3 of Lelipag
[0339] The X-ray powder diffraction pattern of crystalline form 3 of lelipag is Figure 3 Representative peaks include those listed in the following table:
[0340] Angle 2θ(°) Relative strength [%] 3.6 29.06 18.7 100.00 20.9 39.98 22.2 52.81 24.2 69.93 24.3 75.28
[0341] Form 3 was recovered only from DMSO and was highly crystalline.
[0342] Characterization of Crystallization Style 4 of Reilippinosus
[0343] The X-ray powder diffraction pattern of lelipagulin in crystalline form 4 is Figure 4 Representative peaks include those listed in the following table:
[0344] Angle 2θ(°) Relative strength [%] 15.0 38.08 16.7 100.00 18.0 73.16 18.7 48.43 18.9 75.35 22.6 53.51 22.7 42.43 24.5 33.19
[0345] When water was added as a co-solvent, pattern 4 was only observed in the wet solids obtained from N,N-dimethylacetamide (DMA) and N-methyl-2-pyrrolidone (NMP).
[0346] Form 4 prepared from NMP / water converts to Form 1 upon drying (even if air dried).
[0347] Sample 4 prepared from DMA / water converted to a predominantly amorphous form with some Form 1 peaks present.
[0348] Characterization of amorphous lelipaque
[0349] The X-ray powder diffraction pattern of amorphous lelipag, as prepared in Example 2f, is Figure 5 XRPD showed a lack of crystallinity.
[0350] Example 6: Thermogravimetric analysis / differential thermal analysis (TGA / DTA)
[0351] Approximately 5 mg of material was weighed into an open aluminum pan and loaded into a simultaneous thermogravimetric analysis / differential thermal analyzer (TGA / DTA) and maintained at room temperature. The sample was then heated from 20°C to 350°C at a rate of 10°C / min, during which the change in sample weight and any differential thermal events (DTA) were recorded. Nitrogen was used as the purge gas with a flow rate of 300 cm 3 / min.
[0352] The TGA / DTA thermogram of lelipag in crystalline form 1 is shown in Figure 6 The TGA / DTA thermogram of lelipagulin in crystalline form 2 is shown in Figure 8 The TGA / DTA thermogram of crystalline form 3 of lelipag is shown in Fig. 9 The TGA / DTA thermogram of lelipagulin in crystalline form 4 is shown in Fig.10 middle.
[0353] Thermogravimetric analysis / differential thermal analysis (TGA / DTA) spectra of the solid state form of lelipag are described in the following table.
[0354] Table 4. Representative TGA / DTA spectra
[0355]
[0356] *Samples were not dried before TGA / DTA analysis
[0357] Example 7: Differential Scanning Calorimetry (DSC)
[0358] To assess the possibility of recrystallization, crystalline Form 1 of lelipag was heated above the melting point and then reheated before cooling back to 20 °C.
[0359] Approximately 1-5 mg of material was weighed into an aluminum DSC pan and sealed non-hermetically with an aluminum lid. The sample pan was then loaded into a TA Instruments Discovery DSC 2500 differential scanning calorimeter equipped with an RC90 cooler. The samples and references were heated to above the melting temperature at a scan rate of 10°C / min and the resulting heat flow response was monitored. The samples were recooled to 20°C and then reheated again above melting at 10°C / min. Nitrogen was used as the compartment purge gas with a flow rate of 50 cm 3 / min.
[0360] The DSC thermogram of lelipag in crystalline form 1 is Figure 7 . A sharp endothermic event (onset at about 127.5°C, peak at about 129.2°C) consistent with the onset of melting in TGA / DTA was observed in the first heating step. No additional events were observed in the first heating step. No thermal events were observed upon cooling after melting. In the second heating step, a weak thermal event was observed at about 193°C, which is potentially attributed to the onset of decomposition.
[0361] Example 8: Dynamic Vapor Sorption (DVS)
[0362] Approximately 10 mg of sample was placed in a mesh vapor sorption balance pan and loaded into a DVS-1 / DVS Intrinsic / DVS Advantage dynamic vapor sorption balance by a surface measurement system. The sample was subjected to a ramp curve from 40%–90% relative humidity (RH) in 10% increments, maintaining the sample at each step until a stable weight (dm / dt 0.004%, minimum step length 30 min, maximum step length 500 min) was reached at 25°C. After the adsorption cycle was completed, the sample was dried to 0% RH using the same procedure, and then the second adsorption cycle returned to 40% RH. Two cycles were performed. Plotting the weight change during the adsorption / desorption cycle allowed the hygroscopic properties of the sample to be determined.
[0363] Lelipag in crystalline Form 1 is non-hygroscopic. The reversible water uptake of crystalline Form 1 between 0% and 90% RH as determined by DVS is 0.1% (w / w).
[0364] XRPD analysis was then performed on any remaining solid and showed that the material was unchanged after DVS analysis and remained crystalline Form 1.
[0365] Example 9: High Performance Liquid Chromatography-Ultraviolet Detection (HPLC-UV)
[0366] Purity analysis was performed using HPLC. Full method details are provided below:
[0367]
[0368] Crystalline Form 1 lelipag was 99.7% pure as determined by relative area.
[0369] Example 10: Single Crystal X-ray Diffraction (SXRD) of Crystalline Form 1 of Lelipag
[0370] When heptane was added as an antisolvent, crystalline Form 1 of lelipag from isopropyl acetate consisted of very large lath-like particles. These particles appeared birefringent under polarized light, consistent with crystalline material.
[0371] A suitable crystal was selected and mounted in a ring using paratone oil. The diffractometer was used to irradiate the sample at 100(2)K with Cu-Kα radiation using a Bruker D8 Venture diffractometer equipped with a Photon III detector operated in shutterless mode. Data were collected. The structure was solved in the Olex2 software package (Dolomanov, OV, Bourhis, LJ, Gildea, RJ, Howard, JAK & Puschmann, HJ Appl. Cryst., 2009, 42, 339-341.) using the ShelXT (intrinsic phasing) (Sheldrick, GM Acta Cryst., 2015, A71, 3-8.) structure solution program and refined using the ShelXL (Sheldrick, GM Acta Cryst., 2015, C71, 3-8.) refinement package using least squares minimization. Data were collected, solved and refined in triclinic space group P-1.
[0372] All non-hydrogen atoms were located in the Fourier map and their positions were refined anisotropically before describing the thermal mobility of all non-hydrogen atoms. Within the asymmetric unit, a complete Rayleigh Pag formula unit was refined. All hydrogen atoms were placed in the calculated positions using the riding model with fixed Uiso (1.2 times for all CH and CH2 groups and 1.5 times for all OH groups).
[0373] The highest residual Fourier peak is found to be Distance from Cl(1A) And the deepest Fourier hole is Distance from Cl(1A)
[0374] The asymmetric unit was found to contain only one complete molecule of lelipag.
[0375] The crystallographic parameters and refinement indicators were found to be as follows:
[0376] Crystal data of lelipampuginose in crystalline form 1 at 100 K
[0377]
[0378] Fractional atomic coordinates of lelipagulin in crystalline form 1 at 100 K
[0379] atom x y z C11 -4187.5(6) 10554.2(6) 8422.0(7) O1 13336.3(14) 1059.1(12) 5066.3(13) O2 14028.7(14) -1175.8(12) 5278.2(13) O3 10406.6(13) 1265.0(12) 5619.4(12) O4 4317.8(13) 6561.9(12) 8015.1(13) O5 2743.1(14) 8690.2(12) 8287.0(13) N1 1964.4(16) 7001.0(14) 8116.5(14) C1 13046.5(19) 31.9(18) 5255.3(16) C2 11519.8(19) -2.1(18) 5466.7(19) C3 10056(2) 1744.5(19) 6842.3(17) C4 8646.2(19) 2946.8(18) 7056.3(17) C5 8141(2) 3307.8(19) 8431.2(17) C6 6728(2) 4522.4(19) 8707.8(17) C7 6898(2) 5728.9(18) 7840.2(17) C8 7417(2) 5375.9(19) 6464.2(18) C9 8828(2) 4155.3(19) 6196.9(18) C10 5501(2) 6946.9(19) 8126.9(19) C11 2993.7(19) 7528.9(18) 8150.8(16) C12 2368.6(19) 5610.1(17) 7897.2(17) C13 3218(2) 5115(2) 6731.8(19) C14 3575(3) 3775(2) 6541(2) C15 3067(2) 2957(2) 7505(2) C16 2221(2) 3454(2) 8667(2) C17 1865(2) 4792(2) 8869.3(19) C18 457.1(19) 7828.0(17) 8255.8(17) C19 -306(2) 8730.7(17) 9200.6(17) C20 -1755(2) 9549.2(18) 9284.5(18) C21 -2430(2) 9449.8(19) 8421(2)
[0380] atom x y z C22 -1705(2) 8522.3(19) 7506.0(19) C23 -258(2) 7711.2(19) 7423.3(17) C11A 3759(6) 1183(6) 7725(6)
[0381] Hydrogen atomic coordinates of lelipagulin in crystalline form 1 at 100 K
[0382] atom x y z H2 14866.39 -1119.59 5156.22 H2A 11501.26 -409.4 4741.57 H2B 11297.39 -581.1 6226.19 H3A 10875.53 1996.6 6908.74 H3B 9926.79 1029.77 7493.85 H4 7864.51 2700.29 6884.7 H5A 7968.77 2535.94 8980.8 H5B 8933.23 3496.95 8629.71 H6A 5907.98 4299.39 8600.63 H6B 6471.15 4750.47 9593.14 H7 7695.2 5956.32 8007.09 H8A 7600 6147.48 5920.94 H8B 6628.42 5193.72 6252.8 H9A 9095.04 3930.04 5309.26 H9B 9644.89 4373.32 6315.81 H10A 5283.63 7226.2 8988.44 H10B 5619.45 7700.8 7522.6 H13 3554.07 5686.84 6067.1 H14 4168.96 3422.88 5746.97 H15 3299.76 2043.32 7368.84 H16 1882.22 2881.73 9329.84 H17 1280.91 5139.29 9667.11 H19 165.47 8788.1 9792.88 H20 -2276.03 10170.76 9927.98 H22 -2194.72 8440.98 6938.12 H23 249.1 7071.88 6794.4
[0383] The structure was observed to have an effective packing, and the calculated density was 1.330 g / cm 3 There are no regions of stray electron density that can be attributed to solvent, nor are there any large cavities or channels in which solvent or water can reside. Packing can be seen when viewing along the unit cell axes a, b, and c. Strong hydrogen bonding interactions were observed between the opposing carboxylic acid termini, providing the drive for the crystallization of lelipag:
[0384] The simulated XRPD 2θ was calculated and compared with the experimental diffraction pattern of crystalline Form 1 of lelipag, and an excellent overlap was observed, as shown in Fig.11 Any deviations in the diffraction pattern can be attributed to temperature differences when the data set was collected.
[0385] Table 5. Simulated XRPD 2θ diffraction pattern of lelipag Form 1 (20 most intense peaks).
[0386]
[0387] Example A-1: Oral capsule (immediate release formulation)
[0388] To prepare a pharmaceutical composition for oral delivery, 0.01 mg to 0.4 mg of a form of lelipag disclosed herein or a pharmaceutically acceptable salt thereof is dissolved in RH4 or another suitable solubilizer, and optionally thickened with silicon dioxide or another suitable thickener, and / or stabilized with butylated hydroxytoluene (BHT) or another suitable stabilizer. The liquid mixture is incorporated into oral dosage units suitable for oral administration, such as hard gelatin capsules.
[0389] Example A-2: Oral capsule (extended release formulation)
[0390] To prepare a pharmaceutical composition for extended release oral delivery, 0.01 mg to 0.4 mg of lelipag or a pharmaceutically acceptable salt thereof is mixed with poloxamer P188 or another suitable solubilizer and / or glyceryl monostearate or another suitable emulsifier. The liquid mixture is incorporated into an oral dosage unit suitable for oral administration such as a hard gelatin capsule. The ratio of the excipients can be varied to control the drug release rate.
[0391] Example A-3: Oral tablet (extended release formulation)
[0392] Tablets are prepared by mixing 0.05 mg-0.4 mg of lelipag or a pharmaceutically acceptable salt thereof with 20%-50% by weight of microcrystalline cellulose, 40%-60% by weight of a release-modifying excipient (such as a blend of hydroxypropylmethylcellulose (HPMC) K4M and HPMC K100LV), and 20%-40% by weight of mannitol, silicon dioxide, magnesium stearate or other suitable excipients. Tablets are prepared by direct compression. The total weight of the compressed tablet is maintained at 100 mg-200 mg.
[0393] The examples and embodiments described herein are for illustrative purposes only, and various modifications or changes suggested to those skilled in the art are intended to be included within the spirit and scope of this application and the appended claims.
Claims
1. A crystalline form of lelipag characterized by: An X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 1, as measured using Cu Ka radiation; or an XRPD pattern having peaks at 8.8±0.2° 2θ, 11.7±0.2° 2θ, and 16.2±0.2° 2θ as measured using Cu Ka radiation; or An XRPD pattern substantially the same as that shown in Figure 2, as measured using Cu Ka radiation; or an XRPD pattern having peaks at 4.1±0.2° 2θ, 15.5±0.2° 2θ, and 16.9±0.2° 2θ as measured using Cu Ka radiation; or An XRPD pattern substantially the same as that shown in Figure 3, as measured using Cu Ka radiation; or an XRPD pattern having peaks at 3.6±0.2° 2θ, 18.7±0.2° 2θ, and 22.2±0.2° 2θ as measured using Cu Ka radiation; or An XRPD pattern substantially the same as that shown in Figure 4, as measured using Cu Ka radiation; or An XRPD pattern having peaks at 15.0±0.2° 2Θ, 16.7±0.2° 2Θ, and 18.0±0.2° 2Θ as measured using Cu Ka radiation.
2. A crystalline form of lelipag (Form 1) characterized by having: An X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 1, as measured using Cu Ka radiation; or an XRPD pattern having peaks at 8.8±0.2° 2θ, 11.7±0.2° 2θ, and 16.2±0.2° 2θ as measured using Cu Ka radiation; or An XRPD pattern substantially the same as shown in any of Figures 12a, 12b, 12c, 12d, 12e, 12f, 13a, 13b, 13c, 13d, 13e, 14a, 14b, 14c, 14d, 14e, 14f, 14g, 15a, 15b, 15c, 16, 17a or 17b, as measured using Cu Ka radiation.
3. The crystalline form of lelipag according to claim 2, wherein the crystalline form is characterized by having an XRPD pattern having peaks at 8.8±0.2°2θ, 11.7±0.2°2θ and 16.2±0.2°2θ as measured using Cu Ka radiation.
4. The crystalline form of lelipag according to claim 2, wherein the crystalline form is characterized by: An X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 1, as measured using Cu Ka radiation; or An XRPD pattern substantially the same as shown in any of Figures 12a, 12b, 12c, 12d, 12e, 12f, 13a, 13b, 13c, 13d, 13e, 14a, 14b, 14c, 14d, 14e, 14f, 14g, 15a, 15b, 15c, 16, 17a or 17b, as measured using Cu Ka radiation.
5. The crystalline form of lelipag according to any one of claims 2-4, further characterized by having: A thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram substantially the same as that shown in FIG6 ; or a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in Figure 7; or showing a differential thermal analysis (DTA) thermogram having a sharp endothermic event with an onset at about 127.2°C; or A DSC thermogram having a sharp endothermic event with an onset at about 127.5°C.
6. The crystalline form of lelipag according to any one of claims 2-5, further characterized by having: Reversible water absorption of up to 0.2% (w / w) between 0% and 90% relative humidity (RH) as measured by dynamic vapor sorption (DVS); or Unchanged XRPD pattern after DVS analysis between 0% and 90% RH.
7. The crystalline form of lelipag according to claim 5, wherein the crystalline form is characterized by: i) an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 1, as measured using Cu Ka radiation; or an XRPD pattern substantially the same as shown in any of Figures 12a, 12b, 12c, 12d, 12e, 12f, 13a, 13b, 13c, 13d, 13e, 14a, 14b, 14c, 14d, 14e, 14f, 14g, 15a, 15b, 15c, 16, 17a, or 17b, as measured using Cu Ka radiation; as well as ii) a thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram substantially the same as that shown in FIG6 ; or A Differential Scanning Calorimetry (DSC) thermogram substantially the same as that shown in FIG7 .
8. The crystalline form of lelipag according to claim 5, wherein the crystalline form is characterized by: i) an XRPD pattern having peaks at 8.8±0.2° 2θ, 11.7±0.2° 2θ, and 16.2±0.2° 2θ as measured using Cu Ka radiation; and ii) showing a differential thermal analysis (DTA) thermogram having an onset at about 127.2°C; or A Differential Scanning Calorimetry (DSC) thermogram has a sharp endothermic event with an onset at about 127.5°C.
9. A crystalline form of lelipag (Form 1) characterized by having unit cell parameters at 100K substantially equal to:
10. A crystalline form of lelipag (Formula 2) characterized by having: An X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 2, as measured using Cu Ka radiation; or an XRPD pattern having peaks at 4.1±0.2° 2θ, 15.5±0.2° 2θ, and 16.9±0.2° 2θ as measured using Cu Ka radiation; or.
11. The crystalline form of lelipag according to claim 10, further characterized by having: A thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram substantially the same as that shown in FIG8 ; or The TGA / DTA thermogram showed weak endothermic and exothermic events from 81 °C to 89 °C and a broad endothermic event with an onset at about 124.7 °C.
12. The crystalline form of lelipag according to claim 11, wherein the crystalline form is characterized by: an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in FIG2 , as measured using Cu Ka radiation; and A Thermogravimetric Analysis / Differential Thermal Analysis (TGA / DTA) thermogram substantially the same as that shown in FIG8 .
13. The crystalline form of lelipag according to claim 11, wherein the crystalline form is characterized by: an XRPD pattern having peaks at 4.1±0.2° 2θ, 15.5±0.2° 2θ, and 16.9±0.2° 2θ as measured using Cu Ka radiation; and The TGA / DTA thermogram showed weak endothermic and exothermic events from 81 °C to 89 °C and a broad endothermic event with an onset at about 124.7 °C.
14. The crystalline form of lelipag according to any one of claims 10-13, wherein the crystalline form of lelipag is further characterized by having an XRPD that upon heating converts to the crystalline form of lelipag according to any one of claims 2-9.
15. The crystalline form of lelipag according to any one of claims 10-14, wherein the lelipag in crystalline Form 2 is further characterized as a dimethyl sulfoxide solvate.
16. A crystalline form of lelipag (Form 3) characterized by having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 3, as measured using Cu Ka radiation; or An XRPD pattern having peaks at 3.6±0.2° 2Θ, 18.7±0.2° 2Θ, and 22.2±0.2° 2Θ, as measured using Cu Ka radiation.
17. The crystalline form of lelipag according to claim 16, further characterized by having: A thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram substantially the same as that shown in FIG9 ; or A thermogravimetric analysis (TGA) trace showing a mass loss of about 17.8% from the onset of heating to about 238°C; or A differential thermal analysis (DTA) thermogram was shown with a sharp endothermic event with an onset at about 74.6°C.
18. The crystalline form of lelipag according to claim 17, wherein the crystalline form is characterized by: an XRPD pattern substantially the same as that shown in FIG3 , as measured using Cu Ka radiation; and A Thermogravimetric Analysis / Differential Thermal Analysis (TGA / DTA) thermogram substantially the same as that shown in FIG. 9 .
19. The crystalline form of lelipag according to claim 17, wherein the crystalline form is characterized by: an XRPD pattern having peaks at 3.6±0.2° 2θ, 18.7±0.2° 2θ, and 22.2±0.2° 2θ as measured using Cu Ka radiation; and A thermogravimetric analysis (TGA) trace showing a mass loss of about 17.8% from the onset of heating to about 238°C; or a differential thermal analysis (DTA) thermogram showing a sharp endothermic event with an onset at about 74.6°C.
20. The crystalline form of lelipag according to any one of claims 16-19, further characterized as a hydrate.
21. A crystalline form of lelipag (Formula 4) characterized by having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 4, as measured using Cu Ka radiation; or An XRPD pattern having peaks at 15.0±0.2° 2Θ, 16.7±0.2° 2Θ, and 18.0±0.2° 2Θ as measured using Cu Ka radiation.
22. The crystalline form of lelipag according to claim 21, further characterized by having a thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram substantially the same as that shown in Figure 10; or Differential thermal analysis (DTA) thermograms showing a broad endothermic event with an onset at about 29.0°C, a sharp endothermic event with an onset at about 127.8°C, or both.
23. The crystalline form of lelipag according to claim 22, wherein the crystalline form is characterized by having: an XRPD pattern substantially the same as that shown in FIG4 , as measured using Cu Ka radiation; and A Thermogravimetric Analysis / Differential Thermal Analysis (TGA / DTA) thermogram substantially the same as that shown in FIG. 10 .
24. The crystalline form of lelipag according to claim 22, wherein the crystalline form is characterized by having: an XRPD pattern having peaks at 15.0±0.2° 2θ, 16.7±0.2° 2θ, and 18.0±0.2° 2θ as measured using Cu Ka radiation; and Differential thermal analysis (DTA) thermograms showing a broad endothermic event with an onset at about 29.0°C, a sharp endothermic event with an onset at about 127.8°C, or both.
25. The crystalline form of lelipag according to any one of claims 21-24, wherein the crystalline form of lelipag is further characterized by having an XRPD that upon drying converts to the crystalline form of lelipag according to any one of claims 2-9.
26. The crystalline form of lelipag according to any one of claims 21-24, wherein the crystalline form of lelipag is further characterized by having an XRPD that converts to an amorphous form of lelipag upon drying.
27. Amorphous lelipag characterized by having an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity.
28. The amorphous form of lelipag according to claim 24, wherein the amorphous form of lelipag is further characterized by converting upon drying to the crystalline form of lelipag according to any one of claims 2-9.
29. A pharmaceutical composition comprising crystalline lelipag according to any one of claims 1-26 and at least one pharmaceutically acceptable excipient.
30. A pharmaceutical composition comprising the amorphous form according to claim 27 or 28 and at least one pharmaceutically acceptable excipient.
31. The pharmaceutical composition of claim 29 or 30, wherein the pharmaceutical composition is formulated in the form of a solid form pharmaceutical composition suitable for administration to a subject by oral administration, intranasal administration, or inhalation.
32. The pharmaceutical composition of claim 29, 30 or 31, wherein the pharmaceutical composition is in the form of a tablet, a pill or a capsule.
33. The pharmaceutical composition of claim 29, 30 or 31, wherein the pharmaceutical composition is administered to a subject using a dry powder inhaler (DPI) or a metered dose inhaler (MDI).
34. A method of treating pulmonary arterial hypertension (PAH) in a subject in need thereof, comprising administering lelipag according to any one of claims 1 to 28, or a pharmaceutical composition according to any one of claims 29 to 33.
35. The method of claim 34, wherein the PAH is selected from: (a) Idiopathic PAH; (b) familial PAH; (c) PAH associated with a collagen vascular disease selected from the group consisting of scleroderma, CREST syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis; (d) Takayasu's arteritis, polymyositis and dermatomyositis; (e) PAH associated with a congenital heart disease selected from the group consisting of atrial septic defect (ASD), ventricular septic defect (VSD), and patent ductus arteriosus in a patient; (f) PAH associated with portal hypertension; (g) PAH associated with HIV infection; (h) PAH associated with ingestion of drugs or toxins; PAH associated with hereditary hemorrhagic telangiectasia; (i) PAH associated with splenectomy; (j) PAH associated with significant venous or capillary involvement; (k) PAH associated with pulmonary veno-occlusive disease (PVOD); and (l) PAH associated with pulmonary capillary hemangiomatosis (PCH) in patients.
36. The method of claim 34, wherein the PAH is a World Health Organization (WHO) Group 1 PAH.
37. The method of any one of claims 34 to 36, wherein the subject has World Health Organization (WHO) / New York Heart Association (NYHA) functional class II to IV symptoms.
38. A method of synthesizing amorphous lelipag comprising converting a crystalline form of lelipag into an amorphous form of lelipag, wherein the amorphous lelipag is characterized by having an X-ray powder diffraction (XRPD) pattern showing a lack of crystallinity.
39. The method of claim 38, wherein the method comprises drying the crystalline form of lelipag according to any one of claims 21-24.
40. The method of claim 38, wherein the method comprises lyophilizing a solution of lelipipag in an organic solvent.
41. The method of claim 40, wherein the organic solvent is 1,4-dioxane.
42. The method of claim 40 or 41, wherein the concentration of lelipag in the solution is at most 5 mg / mL.
43. The method of claim 40 or 41, wherein the concentration of the lelipag solution is at most 3 mg / mL.
Citation Information
Patent Citations
Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
US10668033B2
Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
US20200375930A1
Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
US8895776B2
Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
WO2009117095A1
